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“Gräv ut slöhetens bomull ur förståndets öra, så att från de döde visdomsordet må tränga in 
i ditt öra” 
–  Shaikh Saadi  
(Persisk poet 1210–1292) 
  
ABSTRACT 
Background: A new capacitance-based automatic urinometer (AU) facilitates continuous 
urine output (UO) measurement, which may help to predict and diagnose acute kidney 
injury (AKI). To prevent mismeasurement due to bacterial, albumin or free hemoglobin 
biofilm, a water-soluble capsule with silicone oil has been integrated in the device.  
Aims: To assess: the performance of a new capacitance-based AU in adult patients in a 
cardiothoracic intensive care unit (ICU) and compare it with a manual urinometer (MU) in 
regard of bias, precision, temporal deviation and to evaluate the staff’s opinion of the AU 
(Study I); a modified capacitance-based AU in comparison with an MU regarding 
measuring bias among patients ≤10 kg in a pediatric intensive care unit and to evaluate the 
staff’s opinion of the AU (Study II); whether a silicone oil-coated polypropylene plastic 
surface, as used in an AU, may reduce early microbial biofilm formation and to identify the 
silicone oil target; to compare polypropylene with polystyrene and low with medium 
viscosity silicone oil regarding the propensity to impede biofilm formation (Study III); if 
silicone oil added to the measuring chamber of the AU may prevent the rise in capacitance 
due to albumin or free hemoglobin biofilm, allowing the device to function for longer 
periods of time (Study IV).  
Methods: Study I-II were prospective observational cohort studies, whereas Study III-IV 
were experimental prospective in vitro studies. Study I: 34 postoperative patients had their 
hourly UO registered with either an AU (n=220) or an MU (n=188), which were validated 
by cylinder measurements and analyzed using the Bland-Altman method. The temporal 
deviation of the MU measurements was recorded (n=108) and at the end, the nursing staff 
(n=28) evaluated the AU. Study II: The hourly diuresis was measured using either an AU 
(n=127) or an MU (n=83) in 12 children (weight ≤10 kg) and validation was carried out 
using a measuring cylinder. Thereafter, the nursing staff (n=18) evaluated the AU. Study 
III: Clear flat-bottomed wells of either polypropylene or polystyrene were pretreated with 
silicone oil of low or medium viscosity, after which a panel of microbes, including common 
uropathogenic bacteria and Candida albicans, were added. The plates were left for 3 days 
and the amount of biofilm formation was assessed using the crystal violet assay. Study IV: 
A solution of Ringer’s acetate mixed with either albumin or free hemoglobin was run 
through an AU with either a water-soluble capsule with silicone oil (n=20) or not (n=20) 
and the derived 400-500 capacitance measurements, respectively, were retrieved from the 
AU device and analyzed. 
Results: Study I: The AU had a smaller mean bias (+1.9 mL) than the MU (+5.3 mL) 
(p<0.0001). Defined by their limits of agreements (±15.2 mL AU vs. ±16.6 mL MU, 
p=0.11), the measurement precision of the two urinometers were similar. The AU had 
inherently no temporal deviation, whereas the mean temporal deviation of the MU was ±7.4 
minutes (±12.4%) (p<0.0001). The nursing staff rated the AU significantly higher than the 
MU in terms of user-friendliness, measuring reliability, efficacy and safety. Study II: The 
AU and the MU had a mean bias of −1.1 mL (CI, -0.6 to -1.5) and -0.6 mL (CI, ±0.0 to 
-1.2) respectively (p=0.21). The participating staff considered the AU significantly easier 
to learn, use and handle compared with the MU. Study III: Polypropylene plastic exhibited 
less biofilm growth than polystyrene. Silicone oil, irrespective of viscosity, significantly 
decreased biofilm formation by common uropathogenic bacteria, including ESBL-
producing and multi-drug resistant strains, as well as C. albicans. E. coli curli fimbriae 
were established as the main focus of silicone oil. Study IV: The mean increase in 
capacitance with albumin 3 g/L group was 257±96 without and 105±32 with silicone oil, 
respectively, during 24 hours. After ten hours of registration, differences between the two 
albumin groups reached statistical significance. For the free hemoglobin groups (0.01 g/L), 
the mean increase in capacitance was 190±174 with silicone oil and 324±78 without. A 
significant difference between the free hemoglobin groups was seen after 20 hours and 
onwards. 
Conclusions: For adult postoperative patients, the AU was non-inferior to the MU with 
regard to measuring precision and significantly better than the MU in terms of bias and 
temporal deviation (Study I); for children weighing ≤10 kg, the urinometers were 
comparable in performance (Study II); staff consistently appraised the AU significantly 
higher than the MU in terms of user-friendliness, reliability, safety and efficacy (Study I 
and II). Both low and medium viscosity silicone oil coating of a polypropylene surface 
decreased biofilm formation from common uropathogenic bacteria including Candida 
albicans and the biofilm-promoting factor curli fimbriae was identified as a plausible target 
(Study III); coating of the capacitance measurement membrane of the AU by albumin or 
free hemoglobin significantly disturbed the capacitance measurement capability of the AU, 
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1 INTRODUCTION AND BACKGROUND 
1.1 WHY REGISTER URINE OUTPUT 
For hospitalized patients, particularly for those in the intensive care unit (ICU), essential 
physiological parameters, including arterial saturation, heart rate, blood pressure, 
temperature and respiration rate, are routinely recorded and displayed on the patient data 
monitoring system. The used measuring devices will warn the staff if the monitored values 
are not within the set reference range, whereupon, when necessary, they may help to reduce  
risk for organ failure and ultimately death. 
Urine output (UO) is a vital part of the patient´s fluid turnover, representing the lion’s share 
of fluid output and corresponds to approximately 1500 mL/day in a resting adult person. In 
contrast to fluid intake, which is commonly automatically registered via pumps and 
syringes, UO is virtually still exclusively recorded manually.  
Measuring UO hourly may warn of acute kidney injury (AKI), which is not an unusual 
problem after major surgery and periods of hemodynamic instability (1, 2). AKI occurs in 
more than 55% of ICU patients (3) while cardiac surgery has been associated with up to 
30% incidence of AKI (4). Ischemia, sepsis and toxic medication are considered the most 
frequent triggers of AKI in both children and adults (5). In one study, 25% of pediatric ICU 
patients with AKI died within 4 weeks, whereas the mortality rate in children without AKI 
was 2.7% during the same period (6).  
UO is included alongside creatinine and glomerular filtration rate (GFR) in the 




Figure 1. Internationally used systems, RIFLE (Risk Injury Failure Loss and End-stage renal disease, left), AKIN 
(Acute Kidney Injury Network, middle), and KDIGO (Kidney Disease Improving Global Outcome, right) to 




Serum creatinine has a low sensitivity for AKI as almost 50% of the GFR must be lost 
before a change in serum creatinine may be detected (9). Although the importance of UO as 
a solitary parameter to reflect kidney function has been debated, continuous monitoring of 
UO in addition to renal laboratory parameters may help to identify AKI (10-12) and be 
related to outcome. In a prospective study by Macedo et al. including 317 ICU patients, UO 
was found to be both an early and sensitive marker for AKI and correlated to an increased 
mortality rate in ICU patients (13). In another study by Kellum et al. (14), isolated oliguria 
in stage 2 and 3 AKI was associated with a decreased 1-year survival. Moreover, prediction 
of both short- and long-term risk of death or renal replacement therapy was greatest when 
both the serum creatinine and the UO criteria were met together. 
UO is probably a more sensitive but less specific criterion that needs to be addressed in 
context with the patient’s clinical status and medical history. In a study by Prowle et al., it 
was found that solitary oliguria, without taking other parameters into consideration, was 
only an average predictor of AKI. However, if the patient was hemodynamically unstable 
or in need of incrementing vasopressor support, oliguria was a clinically helpful indicator to 
identify patients in danger of developing AKI (15). Although a low UO is usually 
associated with pending or manifest AKI, UO might in some cases of AKI also increase, 
e.g. in acute interstitial nephritis. Furthermore, the patient’s fluid status will influence the 
UO. Hypovolemia for instance will trigger a low UO without the absolute need of 
concomitant kidney injury (9).  
UO during cardiopulmonary bypass (CPB) has been shown to be independently associated 
with the risk for developing AKI (16) and oliguria post cardiac surgery in association with a 
positive fluid balance has been shown to better predict longer hospital length of stay (LOS) 
than oliguria alone (17).  
Interestingly, hourly UO is one of six simple parameters (heart rate, systolic blood pressure, 
respiratory rate, temperature, state of consciousness, UO) that are included in the modified 
early waring score (MEWS) score, which is used to identify deteriorating patients on 
hospital wards who may need intensive care (Table 1) (18). It is also one of 10 vital 
parameters included in another early warning system called 10 signs of vitality (10 SOV) 
(Table 2) (18). Several other therapeutic protocols use UO to evaluate patients’ response to 







Table 1. Urine output is included in the MEWS (modified early warning score), which is used to identify 
deteriorating patients on hospital wards who may need intensive care (18). 
 
Score 3 2 1 0 1 2 3 
Respiratory rate, per min – £8 – 9-14 15-20 21-29 >29 
Heart rate, per min – £40 41-50 51-100 101-110 111-129 >129 
Systolic blood pressure, mm Hg £70 71-80 81-100 101-199 – ³200 – 
Urine output, mL×kg-1×h-1 Nil <0.5 – – – – – 
Temperature, °C – £35 35.1-36 36.1-38 38.1-38.5 ³38.6 – 
Neurological – – – A V P U 
The score for each parameter is recorded at the time that observations are taken. If the total is four or 






Table 2. Urine output is one of 10 vital parameters included in another early warning system called 10 SOV 
(10 Signs Of Vitality) (18). 
 
Sign Abnormal range  
Temperature ³38°C Unweighted measures 
Pulse <50 or >100/min  
Pain New or significant  
Respiratory rate <6 or >20/min Weighted measures 
SaO2 <90% or increasing O2 requirement  
Blood pressure 
 
Mean arterial pressure<60 mm Hg or 
systolic blood pressure <90 mm Hg 
 
Level of consciousness 
 
Agitation, anxiety, apathy, lethargy, 




<30 mL/h or <100 mL/4 h excluding 
renal failure 
 
Capillary refill >3 s  
Temperature <36°C  
Lactic acid and metabolic acidosis >2 meq/L or base deficit ³5 meq/L  
Any one abnormality of the above signs triggers an assessment by the bedside nurse of all 10 signs. 
Presence of ³2 weighted abnormalities suggests significant hypoxia or hypoperfusion, thereby triggering 
a mobilization of the Rapid Response Team. 
 
1.2 MANUAL REGISTRATION OF URINE OUTPUT 
UO is manually registered recurrently (usually hourly) by the nursing staff in wards and in 
ICUs. Manual measuring is based on visual evaluation of urinometers and collection bags 
and data are documented manually. UO of ICU patients is gathered in a graded container 
that usually has a maximal volume of approximately 500 mL. The container is attached to a 
plastic bag that has a volume of a 1500-3000 mL.  
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1.2.1 Disadvantages with manual registration of urine output 
Manual registration of UO requires a considerable amount of time and effort by the 
working staff. The whole process of recording UO manually requires up to two minutes 
(23). In an ICU with 12 patients, this translates to 24 minutes per hour and 9.5 hours per 
day. Likewise, this corresponds to 292 hours per ICU bed and year. Due to lack of staff 
and/or excess workload, the manual recording of UO is usually not possible in all wards 
where it would have been needed. Thus, patients at risk of developing AKI may be 
neglected. 
There are several risks associated with incorrect manual UO recording. First, registrations 
may not be carried out at exactly a full hour, leading to a false hourly UO measurement. For 
example, a 5 minute-error is introduced if one measurement is taken 3 minutes before full 
hour and the subsequent measurement is taken 2 minutes after full hour. This translates into 
an error of 8%. In one study of manual UO, the mean time error in routine ICU monitoring 
was found to be 16% ±15% (24). Second, the visual assessment of the urine level must be 
done meticulously keeping the eyes at the level of the urine, which otherwise leads to a 
false recording. Third, manual data-recording, whether by pencil or into an electronic 
patient data management system, is another source of error. In contrast to an automatic 
urinometer (AU), manual urinometers (MU) do not emit an alarm in case the system is 
mispositioned or recordings are not within the set reference range. Furthermore, manual 
emptying of the measuring chamber into the collection bag implies a theoretical risk of 
infection upon contact with the urinometer. The numerous obstacles involved in manual 
UO recording as depicted above, have questioned the trustworthiness of MU measurements 
(25). 
1.3 AUTOMATIC URINOMETERS 
Several AUs have been developed to facilitate hourly UO diuresis measurement, whereby 
different methods to measure UO have been applied. Measuring techniques used include 
droplet-based (23), electromagnetic switch (26), high precision scale (27, 28), air pressure 
based volumetric pump (Sentinel®, Serenno Medical, Israel), temperature exchange based 
electronic sensor (Clarity RMSÔ, RenalSense, Israel) (29), weight sensor (Sensica UO®, 
Adaptec Medical Devices, US), motor-pump, speed-based calculation (HS-UM1®, 
Hyupsung Medical, South Korea), artificial intelligence-driven system to support predictive 
analytics (Accuryn Monitoring System®, Potrero Medical, US) (24) and capacitance (30). 
Some AUs have not reached or seem to have disappeared from the market (23), and some 
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are being tested in clinical practice (Sentinel®, Serenno Medical, Israel). Most of these 
techniques show according to their manufacturer excellent performance, and high accuracy, 
including at low and high UO flow rates. However, very few techniques have been 
clinically validated and usually results of ongoing or planned studies have not been 
published in international medical journals. We have only found one technique in current 
clinical use that has been clinically validated (29), except for the capacitance technique, 
which is evaluated in this thesis.  
1.3.1 The capacitance technique for AU measurements (Sippi®) 
The capacitance technique is used in an AU developed by a Swedish startup company 
(Sippi®, Observe Medical, Gothenburg, Sweden). This device comprises two units: a base 
unit to which a disposable unit is attached (Figure 2).  
 
 
FIGURE 2. Overview of the evaluated new automatic urinometer (Sippi®, Observe Medical, Gothenburg).  
(Reprinted with permission from Observe Medical). 
 
This AU is attached to the urinary catheter from where urine flows into the antechamber. In 
the antechamber, urine dissolves a capsule containing silicone oil that is transferred with 
the urine to the measuring chamber located just below. Change in capacitance between two 
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sensors is used to estimate the urine volume within the measuring chamber and the urine 
volume is constantly documented automatically. After measurement, when a volume of 16-
18 mL is attained, urine will depart automatically from the chamber using a siphon 
technique to a collection bag.  
1.3.2 Advantages with an automatic urinometer 
An AU has several potential advantages compared with a traditional MU. First, an AU may 
reduce human error. Second, it should save the work load of the nursing staff (31, 32). 
Third, the applied electronic technique to measure UO may be used to warn for looming 
AKI in a complicated care environment (33) and also enables the implementation of kidney 
injury criteria such as AKIN and KDIGO. Fourth, the use of an AU should help clinicians 
to improve monitoring and forecasting the patient´s fluid balance. The importance of 
continuous monitoring of UO for AKI and fluid management in critically ill patients has 
been emphasized by leading nephrologists and critical care experts (12, 13, 17, 25, 34, 35). 
In a retrospective study of close to 16,000 ICU patients, intensive monitoring of UO 
(defined as hourly recordings and no gaps >3 hours for the first 48 hours after ICU 
admission) was linked to better detection of AKI and lessened 30-day mortality in AKI 
patients, in addition to a decreased fluid overload for all patients (23). Fifth, "no-contact" 
data transmission may lessen the risk of cross-infection of bacteria and virus, including 
SARS-CoV-2, between ICU patients and staff. Sixth, AUs may enable measurement of UO 
in normal wards. Commonly, staff shortage does not allow manual recordings of UO to a 
desirable degree and this may help to identify patients at risk of developing AKI. Seventh, 
minute-to-minute recording of UO may help to identify sepsis at an early stage (36).  
1.3.3 Obstacles to introducing automatic urinometers 
As discussed above, very few AUs are currently used clinically and only one has been 
clinically validated (29). The numerous techniques used for automatic urine measurements 
indicate the complexity in developing a solid measurement technique for clinical use. Apart 
from being accurate at various rates of urine flow, the AU should be easy to handle, robust, 
capable of measuring urine with varying concentrations in electrolytes, urea, creatinine, 
osmolality, glucose etc., as well as to be competitive in price and to allow communication 
with common patient data management systems.  
The AU Sippi® is currently in use in several ICUs around Europe. However, every new 
device needs to be scientifically validated and our aim, in the first part of this thesis, was to 




1.4.1 Definition  
Biofilm is composed of extracellular polymeric substances (EPS) containing primarily 
polysaccharides, proteins and extracellular DNA (37). These are produced by most bacteria 
and candida (37, 38), enabling the microorganisms to be irrevocably accumulated and fixed 
to a surface, making their elimination difficult (Figure 3). Biofilm may be produced on 
both host tissue cells, such as uroepithelial cells, and abiotic surfaces, including urinometers 
and indwelling urinary catheters. As an example, in a study by Sabir et al., bacterial biofilm 
was found in 73.4% of patients having symptoms of a catheter-associated urinary tract 
infection, underscoring the impact of biofilm (39). If released from the biofilm, 
microorganisms may instigate life-threatening infections that need long hospital treatment.  
 
 
FIGURE 3. A scanning electron microscopic image showing Staphylococcus aureus bacteria on an indwelling 
catheter. Biofilm is seen as the sticky-looking substance between the round bacteria. (Reprinted with 
permission from Public Health Image Library/Centers for Disease Control and Prevention). 
 
1.4.2 Biofilm formation 
Biofilm is formed in several steps (40, 41) (Figure 4). In short, free-living (planktonic) 
microbes initially interact briefly and intermittently with a surface (reversible attachment). 
As microbes adapt to the surface, special surface-sensing features are expressed, the cyclic 
adenosine monophosphate level is increased within the cells and more and more cells will 
attach to the surface and remain so for longer periods of time (early biofilm formation). The 
cells will finally enter into an irreversible attachment stage, in which cells are stuck to the 
surface and start producing an extracellular matrix (mature biofilm). Finally, some 
microbes will be released from the biofilm (dispersal phase) and these microbes are often 
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phenotypically and sometimes also genotypically, transformed. Throughout this process, 
complex signaling is thought to take place between the microbes (42).  
 
FIGURE 4. The different phases in biofilm formation. (Illustration by Martin Slettengren).  
1.4.3 Virulence factors 
Bacteria possess different virulence factors to resist the host defense mechanisms and to 
express biofilm. Those virulence factors, here exemplified by uropathogenic Escherichia 
coli, can be divided into different groups based on the underlying mode of action (Figure 
5). Adhesins (e.g. fimbriae or pili) mediate adherence to host cells (43). Toxins (e.g. 
lipopolysaccharides and haemolysin) may destroy host immune effector cells and enable 
the bacteria to penetrate deeper into issue. Iron acquisition mechanisms (e.g. siderophores) 
are vital for the bacteria to survive in the iron-depleted environment of the urinary tract. 
Immune evasion (e.g. cellulose) is used to escape from the host immune cells by biofilm 
production, intracellular hiding or to suppress the pro-inflammatory response. Finally, E. 
coli is equipped with multiple rotating helical filaments, termed flagella, enabling the 
bacteria to swim, for example, against the direction of the urine flow (44). 
In Study III we investigated the effect of different virulence factors of uropathogenic E. 
coli strains. More specifically, we studied type 1 fimbriae, curli and cellulose. Type 1 
fimbriae, adhesins, are helical structures composed of several subunits. Those fimbriae are 
most commonly produced through the chaperone-usher pathway in which chaperones fold 
the different subunits of the fimbriae in the periplasm of the bacteria and subsequently a 
protein, the usher, assemble the fimbriae in the outer membrane (45). One such usher, 
which is essential to fimbriae biogenesis, is FimD.  
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Curli, an amyloid, is also an adhesin and a major part of the extracellular matrix, that 
promotes cell accumulation, adhesion to surfaces and biofilm formation (41). It is 
composed of a large number of the major subunit curli specific gene (Csg)A, which after 
polymerization is transported across the outer cell membrane to form the functional fiber 
exposed at the bacterial surface. This transport is mediated via the nucleator subunit CsgB 
(46).  
Cellulose is a polymer consisting of repeating chains of glucose molecules linked via β-1,4 
glycosidic linkages, synthesized by glycosyltransferases located in the membrane. Linked 
to the synthesis is membrane translocation through a channel constituted by cellulose 
synthase. This synthesis and translocation process are catalyzed in bacteria by the inner 
membrane-associated bacterial cellulose synthase (Bcs)A and BcsB subunits (47). Cellulose 
provides structure and protection to bacteria in biofilm through the formation of a matrix. 
Moreover, cellulose may help bacteria to reduce the host’s immune response as well as cell 
aggregation, enabling the biofilm to reach the surface of the culture where oxygen is 





FIGURE 5. Virulence factors, including groups, of uropathogenic Escherichia coli (Reprinted with permission 






Normally, healthy kidneys only filter very small amounts of protein into the urine as almost 
all protein molecules are too large to pass through glomeruli. Proteinuria may be due to 
diseases of the glomeruli e.g. glomerulonephritis or diabetes mellitus, urinary tract 
infection, congestive heart failure, surgery or genetic differences in the glomerular 
endothelial function (49). Proteinuria is a known independent risk factor for AKI (50). In 
patients undergoing cardiac surgery, both preoperative (51) and postoperative (52) 
albuminuria can predict which patients have an increased risk of developing AKI during 
their hospital stay. 
1.4.5 Hemoglobinuria 
Hemolysis occurs due to destruction of red blood cells and results in release of hemoglobin 
into the blood system. The possible causes of hemolysis are many, e.g. toxins, 
hypersplenism, thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, 
bacterial infections, transfusion reactions and malignant hypertension. It may also occur 
during extended operations on CPB or extracorporeal membrane oxygenation (ECMO) as a 
result of mechanical forces e.g. shear stress, hypothermia, turbulent flow, excessive pump 
speed, cavitation or decreased oncotic pressure and clot formation, resulting in complete 
lysis or variable degree of damage of red blood cells (53-55). Excess free hemoglobin (fHb) 
in blood is filtered in the glomeruli of the kidneys that excrete it into the urine, which 
becomes dark red. Severe hemoglobinuria may result in acute tubular necrosis, acute renal 
failure and need for dialysis. In a study by Heijmans et al. (56), patients undergoing 
extended periods of CPB (valve + coronary surgery) had higher levels of plasma fHb than 
shorter periods (coronary surgery) during CPB and the first postoperative hours. In contrast, 
patients undergoing off-pump coronary surgery did not have increased levels of fHb in 
plasma. Patients with AKI (13.4%) exhibited significantly higher fHb serum levels already 
during surgery compared with patients without AKI. 
1.4.6 Biofilm eludes antibiotics 
Microbes form biofilm as an adaptation to external stressors such as the host immune 
response and antibiotics. Once biofilm is formed in the body, the acute microbial infection 
will progressively develop into a chronic infection that is difficult to treat and get rid of. 
Although antibiotics may work in early stages of biofilm, the effect is considerable weaker 
in mature biofilm and biofilm-growing microbes are 10 to 1000 times more resistant toward 
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almost all antiseptics and antibiotics (cell wall biosynthesis inhibitors), compared with 
planktonic microbes (57). 
Several underlying mechanisms have been identified to cause this, e.g. slow or incomplete 
permeation of antibiotics through the biofilm to the bacteria, horizontal gene transfer 
between bacteria, creation of a new chemical microenvironment among the bacteria and the 
progress into a multicellular, heterogenous community of bacteria which is difficult for the 
antibiotics to reach and target (58). Also, microbes may enter into a tolerant state, making 
them capable to survive exposure to an excessive concentration of an antibiotic for some 
time. This may be due to the microbes entering a dormant state with minimal or no growth 
(59). It is estimated that around 80% of chronic and recurrent infections (58) and 65-80% of 
all clinical infections (60) are associated with biofilm.  
1.4.7 Impact on medical devices  
Microbial biofilm may deteriorate the function of medical devices, cause degradation of 
biomaterials and lead to nosocomial bloodstream infections (61, 62) with negative 
consequences for the patient. In the case of an implanted device with biofilm, such as a 
pacemaker or a mechanical heart valve, there is often no other option than to remove the 
infected device and reinstall a new device when the infection is under control (58). As for 
the AU using the capacitance technique, biofilm formation may result in false readings or 
even shutdown, stemming from the progressive biofilm coating of the measuring chamber 
that disturbs the capacitance signal (63). Plausibly, the biofilm may result in a higher risk of 
infection of the patient, regardless of the type of urinometer that is used. Preliminary 
clinical analyses of data in patients undergoing cardiac surgery using the AU Sippi® 
showed that measurements could not be recorded in some patients having albuminuria 
and/or hemoglobinuria or urinary tract infection after 24 hours use of the AU. 
Consequently, finding and validating new methods to decrease the formation of biofilm on 
medical devices, and in this case, the AU, is of clinical importance. 
1.5 BIOFILM PREVENTION 
1.5.1 Measures to decrease biofilm 
Numerous substances and methods have been investigated with the aim to prevent, treat 
and control biofilm in clinical medicine. Methods range from surface modifications (64), 
antimicrobial impregnated surfaces (65), electricity (66, 67), and substances to prevent 
attachment of bacteria to a surface, such as cellobiose dehydrogenase/amylase (68), 
hydrogels (69), silver nanoparticles (70) and honey (71). Treatment may also target 
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established biofilm, e.g. signal interference between bacteria (72), antibiotic-loaded 
nanoparticles to enhance penetration into biofilm (73) and biofilm dispersion (e.g. 
Dispersin B) (74). Medical devices are also being developed that integrate a function of 
early biofilm detection (75). 
1.5.2 Silicone oil 
Silicones, also called polysiloxanes, are polymers consisting of repeating units of 
alternating silicon and oxygen atoms, linked to organic side-chains including 
carbon, hydrogen, and sometimes other elements. Silicone is used in a variety of 
applications, e.g. as lubricants, adhesives, cooking utensils, electrical insulation and in 
medicine. Silicone should not be confused with silicon, which is the chemical element with 




FIGURE 6. Principal chemical structure of the silicone oil polydimethylsiloxane (PDMS).  
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reference. The content of this document has been prepared and reviewed by experts on behalf of ECETOC 
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Silicones come in different forms, from hard plastic to liquid, e.g. silicone oil. Silicone oil 
is extensively used in medicine, for example in breast implants and in vitreous fluid 
substitutes. Safety studies indicate that silicone oil has a low toxicity and is associated with 
a low risk for adverse effects (76, 77). Moreover, silicone oil has no bactericidal effects on 
common microorganisms (78). The most prevalent type of silicone oil is 
polydimethylsiloxanes (PDMS) which is chemically inert, heat-resistant, non-toxic and has 
a low surface tension (Figure 6) (79). Interestingly, preliminary studies indicate that the 
silicone oil PDMS effectively reduce biofouling in polyurethane catheters and that long-
standing slippery liquid infused porous surfaces can be produced on nano-surfaces that also 
inhibit bacterial formation (80, 81). As far as we know, the effect of PDMS has not been 
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investigated on polypropylene plastic, which is the plastic used in the measuring chamber 
of the evaluated new AU (Sippi®) and in parts of the MU (Unometer 500™) that are in 
contact with urine. From our clinical experience, by adding a water-soluble capsule 
containing silicone oil to the antechamber of the device, the problem we initially 
experienced with progressive biofilm formation and deteriorating capacitance signal of the 
AU Sippi®, seemed to be significantly postponed.  
1.5.3 Polypropylene plastic 
The siphon cassette of the studied AU, consisting of the antechamber and the measuring 
chamber, is made up of polypropylene plastic (PP), which is one of the most used plastics 
worldwide and largely utilized in medicine. It has the chemical formula (C3H6)n and is a 
thermoplastic polymer (Figure 7). PP is inherently hydrophobic and oleophilic (82). The 
tendency of biofilm formation varies between type of material. It seems like biofilm by 
some bacteria are more prone to form on hydrophilic surfaces, e.g. glass and stainless steel, 
than on hydrophobic surfaces, such as PP (83). 
 
 




1.5.4 Biofilm prevention in the automatic urinometer SippiÒ 
Based on our initial clinical experience that an integrated water-soluble capsule containing 
silicone oil improved the capacitance measuring capability of the AU SippiÒ, in particular 
for patients with urinary tract infections, albuminuria and hemoglobinuria, we sought to 
determine if the combination of PP and silicone oil had an effect in this regard. As a first 










The specific aims were to: 
 
• Evaluate the performance of a new capacitance-based AU in adult patients in a 
cardiothoracic ICU and compare it with an MU in regard of bias, precision, temporal 
deviation and to evaluate the participating nursing staff’s opinion of the AU compared 
with the MU. 
 
• Compare a modified capacitance-based AU with an MU regarding bias of 
measurements, and to evaluate the participating nursing staff’s opinion of the AU, 
among patients ≤10 kg in a pediatric intensive care unit.  
 
• Investigate whether a silicone oil-coated polypropylene plastic surface, as used in an 
AU, may reduce early biofilm formation by pathogenic bacteria, including ESBL-
producing and multidrug resistant strains, as well as C. albicans, and to investigate 
whether the viscosity of the silicone oil has an impact in this regard.  
 
• Identify the tentative silicone oil target, by using an E. coli strain equipped with curli, 
cellulose and type 1 fimbriae and the isogenic mutants, deficient in one or more of 
these virulence factors.   
 
• Investigate whether albumin or free hemoglobin coating of the capacitance 
measurement membrane of the AU could influence the capacitance measuring 
capability of the AU and whether this could be attenuated by adding silicone oil to 











3.1 THE NEW AUTOMATIC URINOMETER 
The new AU estimates the UO by measuring the change in height of a column of urine in a 
measuring chamber (Figure 8A), after the urine has passed through an antechamber 
(Figure 8C), which contains a water-soluble capsule with silicone oil (Figure 8B) of 
medium viscosity (viscosity 350 mm2/s) (Silbione®, oils 70047, V350, Elkem, Oslo, 
Norway). Thus, the first urine from the patients will dissolve the capsule and transport the 
oil to the measuring chamber, which will get coated with a film of silicone oil. A 
capacitance-based sensor continuously records the height of the urine column through the 
polypropylene plastic wall of the measuring chamber. When the measuring chamber gets 
filled, the urine empties automatically via a siphon. The AU runs on 3 AA batteries, which 
need to be exchanged every three to four months. The standard display shows the 
accumulated UO during the present hour, UO from the last hour and the accumulated UO 
during the present 24-hour period (Figure 9). By pressing a button, each hourly UO of the 
present 24-hour period can be presented as a graph with columns. Optionally, stored data 




FIGURE 8. The measuring chamber (A, lower 2/3) of the automatic urinometer (Sippi®, Observe Medical, 
Gothenburg, Sweden) with a water-soluble capsule (B) containing medium viscosity silicone oil in its ante-







FIGURE 9. The display of the evaluated automatic urinometer (Sippi®, Observe Medical, Gothenburg, 
Sweden). (Reprinted with permission from Observe Medical). 
 
3.1.1 Capacitance measurement 
Capacitance, by definition, is the ability of a component to store an electrical charge and is 
measured in the SI unit farad (symbol: F). Such a component is called a capacitor and 
consists of two metal plates with an insulating layer in between, called dielectric. If a 1 F 
capacitor is charged with 1 coulomb (1 ampere x 1 second) of electrical charge, it will have 
a potential difference of 1 volt between its plates. The capacitance of a capacitor is 
determined by the size and the distance between its plates and the amount and type of 
dielectric. In the AU Sippiâ, the dielectric consists of a column of urine in the measuring 
chamber and the higher the height of urine column in the measuring chamber, the higher 
the capacitance. By measuring the duration it takes to charge and discharge the capacitor, a 
value is acquired of the capacitance that is related to the height of the urine column in the 
measuring chamber. The volume of urine in the measuring chamber can easily be 
calculated based on the change in capacitance. The measurement resolution is 1 mL. In our 
studies we read the visual information on the display every hour according to the inbuilt 
clock. Thus, we could record the information about hourly diuresis at any time. The hourly 
diuresis cycle was determined by the internal clock. The automatic urinometer data can be 
automatically transferred to a patient data management system via Bluetooth, as required, 
usually every solar hour.  
Two capacitance sensors are used, one main sensor (Cm) and one reference sensor (Cr). If 
there is a linear urine inflow to the measuring chamber, Cm will increase, followed by an 
augmentation of Cr in the middle (Figure 10, between A and B), and then Cm will rise 
 
 19 
again. Due to the automatic emptying of the measuring chamber by the built-in siphon, the 
signals from Cm and Cr will decrease rapidly when the chamber self-empties. Nevertheless, 
several external factors, e.g. tilting of the system or biofilm formation within the measuring 
chamber, will affect the signal. The capacitance changes are very low, close to 10-12 F.  
 
 
FIGURE 10. The rise in capacitance over time when the urine volume increases in the measuring chamber. 
Cm = Main plate. Cr = Reference plate. (Reprinted with permission from Observe Medical). 
 
3.1.2 Siphon effect   
A siphon is a liquid reservoir equipped with an inverted U-tube. First, the inverted U-tube is 
filled with liquid after which the siphon may drain liquid from the reservoir to a higher 
level than the reservoir surface and then down again to a lower level. It will do so 
continually without external energy until the level in the reservoir falls below the level in 
the output end of the U-tube (Figure 11). 
The mechanism of the siphon effect has been debated (84, 85). In the past, the atmospheric 
pressure was attributed to push water through the tube, whereas a more recent explanation 
is based on gravitation: The column of water in the downward tube drags water up in the 
upward tube and acts like a chain with the water molecules interacting with each other 
using hydrogen bonds. The maximum height of a liquid siphon depends on the tensile 
strength of water – i.e. the maximum weight that hydrogen bonds are able to lift. It is 
critical that the outflow of the tube lies lower than the inflow of the tube, in that case 
gravitational energy is released at the bottom of the tube and that energy will drag the water 
in the upward tube. If air comes into the tube, the siphon effect will be broken. The siphon 





FIGURE 11. The principle of the siphon effect (A) and how it is constructed in the automatic urinometer (B). 
(A. Reprinted with permission: User: Tomia, CC BY-SA 3.0 <http://creativecommons.org/licenses/by-
sa/3.0/>, via Wikimedia Commons; B. Reprinted with permission from Observe Medical). 
 
 
The AU Sippiâ uses the siphon effect to transport urine from the measuring chamber to the 
urine collection bag. The measuring chamber empties at a volume around 16-18 mL, and 
the exact volume will be registered each time.  
3.1.3 Signal processing algorithm 
An algorithm is used to calculate the urine volume from the measured capacitance values. 
By using signals from the two sensors, the algorithm self-calibrates the device after each 
UO measurement. For every new measurement the AU will sense the existing conditions 
and adapt accordingly.  
3.1.4 Biofilm warning 
Biofilm that is accumulating on the plastic wall of the measuring chamber close to the 
capacitance measurement membrane will affect the capacitance measurement and increase 
the capacitance signal. Biofilm will form from the bottom to the top, resulting in 
progressive failure of the sensors in the lower part of the measuring chamber. This triggers 





FIGURE 12. Progressive biofilm build-up (yellow areas) begins at the bottom of the measuring chamber and 
progresses towards the top. The capacitance expressed as voltage (V) undulates each time the measuring 
chamber is filled and emptied, from A to B. If biofilm is formed, it will occur from the bottom to the top of 
the measuring chamber, resulting in progressive failure of the sensors in the lower part of the measuring 
chamber. This triggers an alarm when reaching critical levels that creates a risk of misreading Cm = Main 




3.2 CLINICAL STUDIES 
3.2.1 Study design 
Study I and Study II were prospective observational cohort studies performed in the 
cardiothoracic ICU at Karolinska University Hospital, and in the pediatric intensive care 
unit at Astrid Lindgren’s Children Hospital, Stockholm Sweden, respectively. Study I 
included 34 adult patients who had undergone cardiac surgery, whereas Study II comprised 
12 patients, with an indwelling urinary catheter before inclusion, weighing <10 kg, which 
corresponds to <12 months of age (86). Based on Study I, we aimed to have about 100 
cylinder and urinometer measurements for each device, the MU and the AU, in Study II. 
Apart from evident exclusion criteria such as anuria and on-going dialysis, we did not have 






3.2.2 Hourly urine measurements with the AU, MU and reference cylinder 
A laboratory technician measured the reference urine volume with a laboratory precision 
measuring cylinder immediately after each hourly measurement with the AU or the MU. 
This person was unaware of the data from the urinometer measurement till after the 
corresponding reference measurement, but aware of which urinometer that was used. 
Immediately prior to each full hour, the AU tube and the MU tube, respectively, were 
emptied. Next, the technician momentarily blocked the tube close to the measuring 
chamber inlet in order to prevent urine inflow during data recording and urine gathering. 
Thereafter, the attending nurse noted the data from the AU screen. Afterwards, the 
technician emptied the attached urine plastic pouch and evaluated the urine volume with the 
reference cylinder. The urine volume that remained in the measuring chamber of the AU, 
when reference measurements had been made, usually varied somewhat between two 
successive measurements. This influenced the measurement of the reference volume. For 
this reason, the technician used a transparent plastic measuring scale delivered by Observe 
Medical (accuracy ±1 mL) to register the remaining urine volume in the measuring 
chamber at each measurement. The temporal deviation of the MU was investigated during a 
separate period in the ICU, by registering the exact time of each measurement (Study I). 
We paired data from each urinometer and from control cylinder used as a reference. 
The MU stores urine in graded chambers, which enables visual reading of the accumulated 
urine volume by the attending nurse before the chambers are emptied manually. A 
prerequisite for correct measurements is that the MU hangs vertically and that the grading 
scale lines are in a horizontal position. In contrast, the AU senses changes in positions that 
interfere with measurements, via a built in accelerometer, and displays an error message on 
its display. Also, an error message appears on the display of the AU when the disposable 
unit needs to be replaced, usually after 7 days or earlier due to severe biofilm formation in 
the measuring chamber.  
3.2.3 Measurements in adult patients (Study I) 
An indwelling urinary catheter was inserted on all adult patients participating in Study I in 
the operating room after induction of anesthesia according to clinical practice. After arrival 
to the ICU, we connected the patients to either the AU (Sippi®, Observe Medical, 
Gothenburg, Sweden) (Figure 2, 8, 9) or to a standard MU (UnoMeter™ 500, Unomedical 






FIGURE 13. A. The manual urinometer UnoMeter™ 500 (A, Study I) and the manual urinometer Unometer™ 
Safeti™ Plus (B, Study II). (Reprinted with permission from Convatec). 
 
We used a laboratory measuring cylinder (250 mL; BLAUBRAND®, BRAND GMBH + 
CO KG, Wertheim, Germany) with a tolerance of ±1 mL as a control. We evaluated the 
urinometers during two separate time periods, first the MU to reflect routine UO 
measurements followed by the AU. There were no cross-overs between the studied 
urinometers. We registered UO data from each patient every hour during daytime for up to 
3 consecutive days, without demanding any minimum number of measurements to be 
entered in the analysis. 
3.2.4 Measurements in pediatric patients (Study II) 
We measured UO in the studied pediatric patients with an AU (Sippi®, Observe Medical 
Nordic AB, Gothenburg, Sweden) and an MU (Unometer™ Safeti™ Plus, Convatec Inc., 
Lejre, Denmark) (Figure 13B) and analyzed and compared data with a gold standard 
measuring cylinder (25 mL; Pyrex® DIN 12680 25:0.5, England). 
The included 12 children either received an AU or an MU, although we registered UO in 2 
children with both urinometers. We measured UO every hour during daytime for up to 4 
sequential days. Clinical data are presented in Table 7. 
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To make the AU and the MU in Study II more comparable, we substituted the original 
single lumen tube of the AU, connected to the indwelling catheter, with a sterile double-
lumen tube. This is the same kind of tube applied in the MU, as it is devised for measuring 
small urine volumes in pediatric patients (Figure 14). 
 
 
FIGURE 14. The double-lumen tube between the patient´s indwelling urinary catheter and the automatic 




FIGURE 15. The automatic urinometer in clinical use, mounted on a pediatric patient’s bed.  
(Photo by Martin Slettengren). 
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3.2.5 Staff view of the urinometers (Study I and II) 
We investigated the staff’s view of the urinometers after ending Study I and II. Each 
participating nursing staff member answered an anonymous questionnaire (Table 6 and 
Table 9 in Results) after a 15-minute introduction course and having used the AU during 3 
days in the respective ICU. The questionnaire included 5 questions considering the easiness 
to learn how to use the AU (question 1) and the user easiness of the AU compared with the 
MU (questions 2-5). There were no missing data. For each question, an ordinal scale 
ranging from 1 to 5 was used. Answers to question 1 were analyzed separately, whereas 
questions 2 to 5 were analyzed by aggregated and personal mean.   
3.3 EXPERIMENTAL STUDIES 
3.3.1 Study design 
Study III and IV were experimental prospective in-vitro studies.  
3.3.2 Bacterial and fungal biofilm formation (Study III) 
3.3.2.1 Bacteria and candida strains 
In Study III we included the uropathogenic Gram-negative bacteria E. coli #12, from a 
child with acute pyelonephritis, E. coli strain CFT073, from a patient with acute 
pyelonephritis, extended spectrum beta lactamase (ESBL)-producing E. coli (CCUG 
55971), Proteus mirabilis (ATCC 29245), Klebsiella pneumoniae (ATCC 13883) and 
multi-drug-resistant (MDR) Klebsiella pneumoniae (CCUG 58547), Pseudomonas 
aeruginosa (ATCC 27853) and the Gram-positive bacteria Enterococcus faecalis (ATCC 
29212) and Staphylococcus aureus (ATCC 29213) and finally the fungus Candida albicans 
(CAC4). E. coli #12, wild-type strain, is equipped with curli, cellulose and type 1 fimbriae, 
which are essential for production of biofilm. To investigate if silicone oil targeted any of 
these virulence factors, we utilized isogenic mutants, lacking at least one of the virulence 
genes. The set of E. coli strains included the wildtype strain #12 (curli+/cellulose +/type 1 
fimbriae+) and its isogenic mutants WE1bcsA (curli+/cellulose−/type 1 fimbriae+), 
WE11csgBA (curli-/cellulose+/type 1 fimbriae+) and WE16csgBA bscA (curli−/cellulose−/ 
type 1 fimbriae+) (87, 88). Type 1 fimbriae were verified by yeast agglutination. We 
created a fim D deficient strain (WKfimD) by the λ-Red mediated homologous 




3.3.2.2 Preparation of bacteria and C. albicans 
In Study III we cultured E. coli #12 and its isogenic mutants on Luria-Bertani (LB) agar 
plates without salt for at least 24 hours to stimulate biofilm formation, while we cultured 
other bacterial strains overnight at 37ºC on blood agar plates. Single bacterial colonies were 
applied for bacterial suspension preparation in phosphate-buffered saline. To circumvent 
bacterial aggregates, we centrifuged the suspension at 1000 revolutions per minute (RPM) 
for 5 min and measured the suspension’s optical density at 600 nm using a 
spectrophotometer and adjusted the suspension to a final concentration of 106 colony 
forming units (CFU) per mL in LB broth without salt. The bacterial concentration was 
verified by viable count. We cultured C. albicans in YPD (yeast peptone dextrose) using 
the same protocol as for bacteria.  
3.3.2.3 Biofilm formation on polypropylene and polystyrene plastic 
To compare the amount of biofilm formed on polypropylene plastic without silicone oil 
with another frequently used plastic, polystyrene, we added E. coli #12 to wells in these 
plastics and left them for 72 hours, where after we measured biofilm formation with a 
crystal violet assay (see below). We studied the effect on polypropylene plastic because the 
measuring chamber of the AU (Sippi®, Observe Medical, Gothenburg, Sweden) consists of 
this plastic. 
3.3.2.4 Silicone oil 
In Study III we used a low-viscosity silicone oil (viscosity 100 mm2/s) and a medium-
viscosity silicone oil (viscosity 350 mm2/s) (Silbione, oils 70047, V100 and V350, Elkem, 
Oslo, Norway). The latter oil was also used in Study IV. The medium-viscosity silicone oil 
is used within the measuring chamber of the AU Sippi®, evaluated in Study I, II and IV. 
3.3.2.5 Pretreatment of microtiter plate with silicone oil 
In Study III we pretreated 96 well clear flat-bottom polypropylene microtiter plates 
(Sigma, USA) with either 300 µl of low viscosity silicone oil (V100) or medium viscosity 
silicone oil (V350) in each well for 5 minutes. Thereafter, we immediately and 
meticulously removed as much oil as possible from each well with a disposable micro-
pipette, leaving merely a thin coating of silicone oil in each well.   
3.3.2.6 Measurement of biofilm formation with crystal violet 
The preparation of bacterial suspension has been described earlier (87). In short, we added 
50 µl of 106 CFU/ mL of bacterial suspension in LB broth without salt together with 150 µl 
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of LB broth without salt, giving a total volume of 200 µl in each polypropylene well with 
and without pre-treatment with the low and medium viscosity silicone oils. We then 
incubated the microtiter plates at 37˚C without shaking for 72 hours. After incubation, we 
removed planktonic cells (single free moving or swimming cells in the medium), washed 
the plates twice with PBS and let them dry in air. We then studied the effect of silicone oil 
on biofilm formation using the crystal violet assay (90). Each well was stained with 220 µl 
of 0.3% crystal violet for 5 minutes, and then destained them with 250 µl of 20% acetone 
and 80% ethanol. The optical density of dissolved crystal violet was determined at 570 nm. 
In Study III all bacterial strains and C. albicans were studied with the same protocol. We 
compared silicone oil treated wells with the untreated controls. To evaluate the viability 
within the biofilm, selected microorganisms, E. coli #12, P. aeruginosa, S. aureus and C. 
albicans, were allowed to grow and form biofilm for 72 hours.  
3.3.2.7 Exclusion of a direct bactericidal or fungicidal effect of silicone oil 
In Study III, we performed growth curves of E. coli #12, S. aureus and C. albicans in order 
to exclude a direct bactericidal or fungicidal effect of the medium viscosity silicone oil. 50 
mL polypropylene Falcon tubes were coated with medium viscosity silicone oil for 5 
minutes, followed by incubation of E. coli #12 or S. aureus in LB broth at 37˚C for 15 
hours, C. albicans in YPD broth at 30˚C for 24 hours. We performed viable counts after 3, 
6, 9 and 15 hours for E. coli #12 and S. aureus, and at 3, 6, 9, 12 and 24 hours for C. 
albicans post incubation with and without oil after serial dilution on blood agar. 
3.3.2.8 Effect of silicone oil on C. albicans hyphae 
C. albicans staining was performed from overnight grown cultures in YPD broth cultured 
with and without oil at 30ºC and centrifuged at 100 RPM. A thin smear was formed on the 
glass slide using an inoculation loop. We let the slides dry for 30 min at 55ºC. We then 
added one drop of blankophor p to the smear and the slides were instantly evaluated using 
ultraviolet light with an Olympus microscope with a 20X objective. 
3.3.3 Albumin and free hemoglobin biofilm (Study IV) 
3.3.3.1 Experimental setup 
In Study IV we explored the effect of silicone oil on biofilm production of albumin and 
fHb, each diluted in a separate solution. The studied solution was stored in a 2500 mL 
container with an outgoing tube, which passed through a peristaltic pump (WELCO WPX1-
P3/328; WELCO Co., Ltd, Tokyo, Japan) powered by a SPS 8041 (Manson Engineering 
Industrials Ltd, Hong Kong, China) with a default of 4.5 Volts. The outgoing tube was then 
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connected to the ingoing tube of the AU (Sippi®) device. To prevent vacuum, air was let 
into the container through a small hole, created with a 18G needle. The solution was thus 
run through the antechamber of the AU and then to its disposable collection bag (Figure 
16). 
The circuit was assembled with either the standard silicone oil capsule in the antechamber 
of the AU or not. The silicone oil capsule was dissolved when the studied solution entered 
the antechamber, whereby the silicone oil was transferred by the solution to the measuring 
chamber, where it adhered to its polypropylene plastic walls (91). Alternatively, the silicone 
oil capsule was removed through a hole created by a soldering iron in the front of the 
antechamber. Thereafter, the hole was sealed with a 3M tape designed for plastic surfaces. 
Every 24 hours a new solution was added to the container and the collection bag was 
emptied. 
 
FIGURE 16. The experimental setup in Study IV. (Illustration by Martin Slettengren). 
 
 
3.3.3.2 Albumin solution 
The first part of Study IV investigated the effect of an albumin solution on capacitance 
measurements with and without silicone oil released from a capsule. Sixty mL of albumin 
(Alburex® 50 g/L, CSL Behring AB, Danderyd, Sweden) was diluted in 960 mL Ringer’s 
Acetate (Baxter International Inc, Deerfield, U.S.), giving a concentration of 3 g albumin/L. 
A new mixture with the same concentration, for each Sippi® peristaltic pump system, was 
produced for every 24 h measurement. The mixture was stored in a 2500 mL container as 
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described above. The peristaltic pump was calibrated to achieve a flow rate of 
approximately 42 mL/h, resulting in an estimated total protein concentration of 3 g/24 h. 
The albumin-Ringer’s Acetate solution was conducted with two parallel groups, 20 times 
with silicone oil and 20 times without. Moreover, two additional experiments with a lower 
albumin concentration, 0.3 g/L and 1.0 g/L, respectively, were conducted.  
3.3.3.3 Free hemoglobin solution 
The second part of Study IV investigated the effect of fHb on capacitance measurement 
with and without silicone oil released from a capsule. fHb was acquired from blood 
remaining in syringes after routine arterial blood gas analysis in patients. Thirty-nine 
separate syringes were used. The residual blood from the syringes was centrifuged with a 
Sigma 1A (Axel Johnson Instruments AB, Stockholm, Sweden) at 3200 RPM for 10 
minutes. The bottom layer, consisting of erythrocytes, was then extracted with a RAININ 
Pipet-lite SL1000 dropper (Rainin Instruments LLC, Oakland, U.S). In order to achieve 
lysis through osmosis, the erythrocyte concentrate was mixed with sterile water giving a 
volume of 10 mL. The fHb concentration was then measured with HEMOCUE® 
PLASMA/LOW Hb 201+ Hemoglobin spectrophotometer (HemoCue America, Brea, 
U.S.). The 10 mL fHb mixture was added to 990 mL of Ringer’s Acetate and stored in 2500 
mL containers as described above. Every 24 h, a new mixture, for each Sippi® peristaltic 
pump system, was produced and used in the same way as before with continuous 
capacitance measurements for 24 h. The fHb solution experiments were conducted 20 times 
with silicone oil and 20 times without. 
3.3.3.4 Extraction of data from the AU 
Measurements of capacitance in the measuring chamber were conducted 60 times/h, i.e. 
1440 times/24h, and data were stored on a removable micro-SD memory card inside the 
device. Analysis of the data was carried out after each 24 h run. In order to reach the micro-
SD memory card, the batteries of the Sippi® base unit were removed with a SANDVIK 
7890 nippers (SNA Europe, Enköping, Sweden). The card was then inserted into a micro-
SD card reader and data transferred to an Excel file. Every 24h, a new disposable set was 
used, except for the 2500 mL container, which was reused after cleaning in a GETINGE 
600 series industrial washer (Getinge Group, Gothenburg, Sweden). Before new tubes and 
disposable sets were connected, the hardware unit was reset and the WELCO pumps and 
the SPS 8041 power unit were calibrated so that all used pumps operated at the same speed 
at 4.5 volt. The containers were refilled with new solutions and the pumps were restarted. 
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Careful initial monitoring of the circuit ensured that it worked as expected and that fluid 
dissolved the silicone oil capsule correctly. 
3.3.3.5 Analysis of capacitance data 
The Sippi® registers capacitance twice every second. Capacitance is the ability to store 
electrical charge and is affected by the height of urine in the measuring chamber, which can 
then be converted by the device to a volume. A mean of the two measurements is logged to 
the micro-SD card of the device once every minute. From these raw data (1440 
measurements/day) the lowest value from every 60-minute period was extracted and stored 
in an Excel file, resulting in 24 measurements from every pump system a day. Twenty runs 
with two parallel systems (one with and one without a silicone oil capsule) yielded a total 
of 480 measurements for each group (24x20). Each stored capacitance value was the lowest 
starting point of every hourly capacitance measurement and represented, compared with the 
initial starting point, the increase in capacitance due to biofilm coating of the inner surface 
of the measuring chamber by albumin or fHb. When the baseline value went up, it indicated 
the growth of biofilm coating. Eventually it reached a critical point after which 
measurement of urine was no longer possible. 
3.4 ETHICS 
The research papers in the thesis followed the principles of the Helsinki Declaration. The 
Regional Ethical Review Board in Stockholm endorsed the studies (Study I: 2012/31-31/2; 
Study II: 2015/666-32; Study IV: 2015/666-32, 2015/2351-32). In Study I, patients were 
included after giving written informed consent, whereas in Study II, involving 12 children, 
informed consent was obtained from at least one parent before inclusion. Study III was a 
pure in vitro study on bacteria without need of ethical approval.  
3.5 STATISTICS  
Data were analyzed with SPSS® statistical program (IBM Corporation, Armonk, NY, USA) 
(Study I, II and IV) and with GraphPad Prism version 5.02 (GraphPad Software, San 
Diego, CA, USA) (Study III).  
Study I and II. We compared variables of patient groups with Student’s t-test when 
normally distributed and the Mann-Whitney U-test when not and Fisher’s exact test if data 
were binary. We used Bland-Altman plots to calculate agreement of the AU and the MU, 
respectively, with cylinder measurements (92-94). Data points show the difference between 
paired measurements. The mean deviation between the respective urinometer and the 
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cylinder formed the mean bias. We drew horizontal lines at mean bias as well as the upper 
and lower limits of agreement (LOA). The LOAs consisted of mean bias ±1.96 x standard 
deviation (SD). The mean bias and the SD are equivalent to the agreement of the AU and 
the MU. We applied an independent samples t-test to test for equality of mean bias, and 
Levene’s test to test for equality of variances in the sample. We estimated absolute value of 
the deviation from exactly one hour between measurements and analyzed by mean, SD and 
95%-limits of agreement. We used the one-sample t-test to test for significance of the staff 
evaluations. 
Study III. Statistical analysis was performed with One-way ANOVA and Bonferroni post-
hoc test to compare multiple groups. One sided difference with p<0.05 was considered 
significant. 
Study IV. Mean and SD were used for descriptive purposes. Group differences were 
assessed with the Mann-Whitney U-test (unpaired) when non-normal distribution in 
continuous variables was ascertained. A p-value of <0.05 was considered significant. All p-


























4.1 STUDY I 
We included in total 408 hourly UO measurements, 220 with the AU and 188 with the MU, 
respectively, from 34 patients, 18 in the AU group and 16 in the MU group (Table 3). 
 
TABLE 3. Clinical variables of the patients in the automatic urinometer (AU) group and the manual 
urinometer (MU) group.  
Variable 
 
AU (n=18) MU (n=16) p 
Female % 28  50  0.29 
Age (years) 68.0 (64.3-75.5) 66.5 (63.5-73.5) 0.75 
Weight (kg) 79.2 ±15.3 80.3 ±7.9 0.83 
Height (cm) 174 ±5.8 172 ±9.8 0.48 
BMI (kg/m²) 1.9 ±0.2 2.0 ±0.2 0.74 
Euroscore II (%) 1.7 (0.9-2.6) 1.6 (0.9-3.1) 0.85 
Preoperative albumin (g/L) 39.0 (36.0-40.3) 38.0 (36.0-39.8) 0.60 
Preoperative creatinine (µmol/L) 82.5 (67.8-97.8) 86.5 (62.5-100) 0.83 
Preoperative eGFR  (mL/min) 78.0 (62.4-104) 75.4 (67.8-89.4) 0.91 
IDDM % 6  6  1.00 
COPD % 6  6  1.00 
LVEF <50% % 33  31  1.00 
Procedure       
    CABG % 28  25  1.00 
    Single valve % 44  44  1.00 
    Valve + CABG % 11  19  0.65 
    Other % 17  13  1.00 
ECC (min) 84.5 (71.5-133) 79.5 (67.0-127) 0.56 
ICU stay (hours) 22.5 (18.8-25.0) 23.0 (18.5-25.3) 0.77 
Ventilation time in ICU (hours) 3.0 (1.0-4.3) 2.5 (1.0-4.8) 0.96 
Inotropes in ICU % 0  6  0.47 
Data are presented as percentages, medians (25th-75th percentile) or means ±SD. 
Abbreviations: BMI = Body mass index; eGFR = Estimated glomerular filtration rate (Cockcroft-Gault equation); IDDM 
= Insulin dependent diabetes mellitus; COPD = Chronic obstructive pulmonary disease; LVEF = Left ventricular 
ejection fraction; CABG = Coronary artery bypass grafting; ECC = Extracorporeal circulation; ICU = Intensive care unit 
 
 
We excluded 5.6% (13/233) of the measurements in the AU group from analysis, almost 
completely because of inappropriate positioning of the AU, e.g. after the patient had 
changed position from the hospital bed to a chair. The median (25th-75th percentile) number 
of UO measurements for each patient was akin for both groups with 10.5 (9.0-16.3) for the 
AU and 12.5 (8.3-14.8) for the MU. We paired every measurement with a reference 
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measurement performed with the measuring cylinder. The mean of the cylinder 
measurements was 65 mL in the AU group and 96 mL in the MU group. Bland-Altman 
calculations (Table 4) and plots (Figure 17) displayed a mean bias of +1.9 mL for the AU 






TABLE 4. Performance parameters of the automatic urinometer (AU) and the manual urinometer (MU)  
measured in milliliters (mL).  
Urinometer parameters (mL) Upper LOA Bias Lower LOA 
 Urinometer n SD SE CI + 𝒙" CI - CI + 𝒙" CI - CI + 𝒙" CI - 
 AU  All 220 7.7 0.5 +18.9 +17.1 +15.4 +2.9 +1.9 +0.9 -11.6 -13.3 -15.1 
  <100mL 176 6.4 0.5 +15.4 +13.8 +12.2 +2.2 +1.3 +0.3 -9.7 -11.3 -12.9 
  ≥100mL 44 11 1.7 +33.5 +27.6 +21.6 +8.0 +4.5 +1.0 -12.6 -18.6 -24.5 
 MU  All 188 8.4 0.6 +23.9 +21.8 +19.8 +6.5 +5.3 +4.1 -9.2 -11.3 -13.4 
  <100mL 124 4.5 0.4 +13.1 +11.6 +10.4 +3.6 +2.8 +2.0 -4.8 -6.2 -7.6 
  ≥100mL 64 12 1.4 +38.1 +33.1 +28.2 +13 +10 +7.2 -8.0 -12.9 -17.9 
For each urinometer, data are presented for all measurements combined, as well as subdivided at a volume of < or 
≥100mL. 
Abbreviations: AU = Automatic urinometer; LOA = Limit of agreement; MU = Manual urinometer; n = Number of 





Figure 17. Bland-Altman plots of the agreement of each urinometer. Volumes are in milliliters (mL). In each 
plot the red lines depict (from above): Upper 95% limit of agreement; Mean bias; Lower 95% limit of 
agreement. Dotted lines depict confidence intervals of each parameter. Three measurements with x-axis 
volumes > 400 mL were omitted for the purpose of visibility. 
 
 
The SD was 7.7 mL and 8.4 mL (p=0.108), respectively, presented by 95% limits of 
agreement intervals placed at ±15.2 mL and ±16.6 mL from the mean. The mean relative 
percentage deviation of the urinometers compared with their paired cylinder measurements 
were ±12.8% for the AU and ±12.7% for the MU (p=0.94). The scatter of the AU did not 
show any obvious change in bias with increasing urine volumes (Figure 17), and displayed 
estimated normality when mapped in a histogram (Figure 18). The MU scatter presented a 
propensity of a greater positive bias with rising UO (Figure 17), and depicted an inclination 













Figure 18. Histograms of the agreement of each urinometer. Volumes are in milliliters (mL). Each bar 
represents an increment of 2 mL. A positive value characterizes an overestimation by the urinometer 





Of the 408 measurements, 146 (36%) were recognized as an UO of <40 mL/h by either the 
used urinometer or the reference measurement. In this group of small urine volumes, the 
AU had a sensitivity of 90%, a specificity of 99%, a positive predictive value of 97% and a 
negative predictive value of 94%. The MU had a sensitivity of 98%, a specificity of 96%, a 
positive predictive value of 92% and a negative predictive value of 99% (Table 5).  
 
 
Table 5. Evaluation of diagnostics of urine output <40mL/h. The automatic urinometer (AU) and the 
manual urinometer (MU) are compared with the measuring cylinder (gold standard). 
Urinometer AU MU 
Sensitivity (%) 90.4 98.2 
Specificity (%) 98.5 96.2 
Positive predictive value (%) 97.4 91.7 
Negative predictive value (%) 94.4 99.2 
 
 
We measured the duration between two sequential measurements and computed the 
absolute difference from exactly a full hour (n=108). The mean time-based variation of the 
MU was ± 7.4 minutes (±12.4%), 95% limits of agreement ±23.9 minutes (±39.8%), which 
should be compared with an absent temporal variation with the AU (p<0.0001).  
 
 37 
All the 28 participating nurses filled out the questionnaires (Table 6) and 93 percent of 
them regarded the AU to be either easy or very easy to learn (question 1). The aggregate 
mean score of question 2 to 5 was 3.8 (SD ±0.9, p<0.0001 compared with mean=3), with 
86% of the nursing staff judging the AU superior to the MU (personal mean>3) (p<0.0001). 
Altogether, 63% of the nurses were in favor of the AU, 5% were in favor of the MU and 




Table 6. Staff opinion (n=28) of the automatic urinometer (AU) compared with the manual urinometer (MU). 
Question Grading 
  5 4 3 2 1 






1. How easy was it to learn to use the automatic 
urinometer? 
39% 54% 7% 0% 0% 
2. Was the collection of urine output data from 
the automatic urinometer easier compared 
with the manual urinometer? 
32% 43% 14% 11% 0% 
  
A lot less Less Same More 
Much 
more 
3. Did you feel that you had less contact with 
the urine bags with the automatic urinometer 
compared with the manual urinometer? 
36% 25% 39% 0% 0% 
  Much 
more 
More Same Less 
Much 
less 
4. Do you think the reliability of the urine output 
data is higher with the automatic urinometer 
than with the manual urinometer? 
21% 64% 7% 0% 7% 
5. Does using the automatic urinometer give you 
more time for other activities? 








4.2 STUDY II 
We included 210 measurements, 127 with the AU and 83 with the MU from 12 patients (six 
AU, four MU, and two patients who used both devices) (Table 7). The mean weight of the 
children was 4.8 kg in both groups and the mean of the cylinder measurements was 18.7 
mL in the AU group and 15.9 mL in the MU group, respectively (p=0.24).  
 
 
Table 7. Characteristics and clinical variables of pediatric patients and number of urine output 
measurements on each patient by the automatic urinometer (AU) and the manual urinometer (MU). 
Patient 
characteristics 
Data at ICU admission ICU stay Urinometer 
recordings  









LOS Time in 
respirator 
AU MU 
4 d M 3.6 Post-op 
esophageal 
atresia 
1.4 22 81 3 d 24 h 10 ⎯ 
4 d M 3.6 Post-op 
diaphragmatic 
hernia 
N/A 21 97 4 d N/A ⎯ 9 




23 82 6 d 5 d 16 ⎯ 
21 
d 
M 3.9 Upper respiratory 
tract infection 
1.8 23 28 3 d 2 d 5 ⎯ 
3 d M 4.1 Post-op 
esophageal 
atresia 
1.0 21 113 3 d 2 d 8 19 
13 
d 
M 4.2 Post ECMO, 
meconium 
aspiration 
7.5 26 35 N/A N/A ⎯ 5 
8 d M 4.3 Post-op 
suspected 
meningocele 
1.1 24 47 3 d 2 d 3 ⎯ 
3 m F 4.4 Cerebral 
hemorrhage, 
seizures 
3.9 12 43 4 d 4 d 13 ⎯ 
2.5 
m 
M 5.2 Post-op biliary 
atresia 
0.4 26 24 13 
h 
N/A ⎯ 7 
3 m M 5.6 Respiratory 
failure in 
VACTERL patient 
1.4 24 29 26 
d 
20 d 65 31 




38 25 10 
d 
N/A ⎯ 12 
17
m 
F 9.0 Bacterial 
meningitis 
2.2 21 13 24 
h 
N/A 7 ⎯ 
Abbreviations: d = days; F = female; h = hours; LOS = length of stay; M = male, m = months; PDR = 
predicted death rate. VACTERL = vertebral defects, anal atresia, cardiac defects, tracheo-esophageal 





The absolute mean bias was -1.1 mL (CI: -0.6; -1.5) and −0.6 mL (CI: ±0.0; -1.2) for the 
AU the MU, respectively (p=0.21). The SD:s were 2.6 mL and 2.8 mL, respectively (Table 
8). The spread of the MU measurements did not show any obvious change of bias with 
increasing urine volume, while the AU had a small propensity to a larger negative bias with 
rising urine volume (Figure 19). When depicted in a histogram, the deviations from the 
reference cylinder values of the AU and the MU displayed near normality (Figure 20). 
 
 
Table 8. Performance parameters of the automatic urinometer (AU) and the manual urinometer 
(MU) measured in milliliters (mL).  
Urinometer parameters Upper LOA Bias Lower LOA  
n SD SE CI + 𝒙# CI - CI + 𝒙# CI - CI + 𝒙# CI - 
AU 127 2.6 0.2 +4.9 +4.1 +3.3 -0.6 -1.1 -1.5 -5.4 -6.2 -7.0 
MU 83 2.8 0.3 +6.1 +5.0 +4.0 ±0.0 -0.6 -1.2 -5.1 -6.2 -7.2 
  p=0.96      p=0.21     
Abbreviations: LOA = Limit of agreement; n = Number of measurements; SD = Standard deviation;  















Figure 19. Bland-Altman plots of the agreement of both urinometer. Volumes are given in milliliters. In each 
plot, the red lines depict (from above): upper 95% limit of agreement; mean bias; lower 95% limit of 





Figure 20. Histograms of the agreement between each urinometer. Volumes are given in milliliters (mL). 
Each bar represents an increment of 2 mL. A positive value represents an overestimation of the urinometer 





18 nurses included in the study filled out the evaluation questionnaire (Table 9). 94% of the 
nurses regarded the AU very easy or easy to learn (Question 1). For Questions 2-5 the 
aggregate mean score was 4.1 (SD ±0.8, p<0.0001 when compared with a mean of 3). 
Approximately 79% of the nurses preferred the AU, 1% preferred the MU and 19% graded 




Table 9. Staff opinion (n=18) of the automatic urinometer compared with the manual urinometer. 
Question Grading 
  5 4 3 2 1 






1. How easy was it to learn to use the automatic 
urinometer? 
50% 44% 6% 0% 0% 
2. Was the collection of urine output data from 
the automatic urinometer easier compared 
with the manual urinometer? 
50% 44% 0% 6% 0% 
  
A lot less Less Same More 
Much 
more 
3. Did you feel that you had less contact with 
the urine bags with the automatic urinometer 
compared with the manual urinometer? 
56% 22% 22% 0% 0% 
  Much 
more 
More Same Less 
Much 
less 
4. Do you think the reliability of the urine output 
data is higher with the automatic urinometer 
than with the manual urinometer? 
11% 61% 28% 0% 0% 
5. Does using the automatic urinometer give you 
more time for other activities? 









4.3 STUDY III  
4.3.1 Biofilm formed on polypropylene compared with polystyrene plastic 
In Study III we studied if the type of plastic influenced biofilm formation, and compared 
polypropylene plastic, used in the AU, with polystyrene. We found that the wild type E. 
coli #12 strain and C. albicans formed significantly less biofilm when cultured on 
polypropylene compared with polystyrene plastic (Figure 21A and Figure 21B; p<0.05 
and p<0.01).  
 
Figure 21. Polypropylene plastic prevented formation of biofilm better than polystyrene, whereas viscosity 
of silicone oil had no impact. The effect of polypropylene compared with polystyrene on biofilm formation 
was analyzed for E. coli #12 (A) and C. albicans (B). Both low and medium viscosity silicone oils significantly 
decreased biofilm formation of E. coli #12 on a polypropylene plate (C). L = Low viscosity. M = Medium 
viscosity. P-value: * ≤0.05; ** ≤0.01; *** ≤0.001; **** ≤0.0001. 
 
4.3.2 Viscosity of silicone oil did not affect prevention of biofilm 
Both low and medium viscosity silicone oil prevented biofilm formation similarly, as 
depicted in Figure 21C for E. coli #12 (p<0.0001). We concentrated on the medium 
viscosity silicone oil, as the water-soluble capsule in the antechamber of the AU contains 
this specific oil. However, we did test all bacteria and C. albicans with both silicone oils 
and found comparable results (Figure 23 and Figure 25).  
4.3.3 Medium viscosity silicone oil decreased biofilm formation  
To explore if silicone oil may prevent the formation of new biofilm by microorganisms, we 
examined the Gram-negative bacteria E. coli CFT073, P. aeruginosa, Prot. mirabilis and K. 
pneumoniae, known to form biofilm (95-97). We found that medium viscosity silicone oil 
significantly inhibited biofilm production in all the tested bacteria (Figure 22A-D; p<0.01 
and p<0.001).  
Figure 1




Figure 22. Medium silicone oil significantly reduced biofilm formation from common pathogens. This effect 
was demonstrated on E. coli CFT073 (A), P. aeruginosa (B), Prot. mirabilis (C), K. pneumoniae (D), ESBL E. coli 
(E), MDR K. pneumoniae (F), S. aureus (G), Ent. faecalis (H) and C. albicans (I). M = Medium viscosity.  
P-value: * ≤0.05; ** ≤0.01; *** ≤0.001; **** ≤0.0001. 
 
Furthermore, medium viscosity silicone oil also decreased biofilm formation of an ESBL-
producing E. coli strain (Figure 22E; p<0.001) and a multidrug resistant K. pneumoniae 
strain (Figure 22F; p<0.0001), giving additional support that silicone oil generally inhibits 
bacterial biofilm formation. In addition, silicone oil significantly decreased biofilm by two 
Gram-positive bacteria, S. aureus and Ent. faecalis (Figure 22G; p<0.001 and Figure 22H, 
p<0.001). Finally, silicone oil significantly inhibited biofilm formation by C. albicans 
(Figure 22I, p<0.05).  
A E. coli CFT073 B P. aeruginosa C P. mirabilis










Figure 23. Low silicone oil significantly reduced biofilm from common pathogens like E. coli CFT073 (A), P. 
aeruginosa (B), Prot. mirabilis (C), K. pneumoniae (D), ESBL E. coli (E), MDR K. pneumoniae (F), Ent. faecalis 
(H) and C. albicans (I), whereas we did not find a significant impact on S. aureus (G). L = Low viscosity. 
P-value: * ≤0.05; ** ≤0.01; *** ≤0.001; **** ≤0.0001. 
 
A P. aeruginosaBE. coli CFT073 C P. mirabilis








Figure 24. Medium viscosity silicone oil affects curli fimbriae. There was a significant reduction of biofilm 
formation of E. coli #12, E. coli (curli+/cellulose−/type 1 fimbriae (fim D+)) and E. coli (curli+/cellulose+/type 
1 fimbriae (fim D−)). Medium viscosity silicone oil did not have a significant effect on biofilm formation of E. 
coli (curli−/cellulose+/type 1 fimbriae (fim D+)) nor on that of the double knock-out E. coli 
(curli−/cellulose/type 1 fimbriae (fim D+)). T1F = Type 1 fimbriae. M = Medium viscosity.  
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Figure 25. Low viscosity silicone oil targets curli fimbriae. A significant reduction of biofilm from E. coli #12, 
E. coli (curli+/cellulose−/type 1 fimbriae (fim D+)) and E. coli (curli+/cellulose+/type 1 fimbriae (fim D−)) was 
noticed. No significant effect of the oil was seen on E. coli (curli-/cellulose+/type 1 fimbriae (fim D+)) nor on 
the double knock-out E. coli (curli−/cellulose−/type 1 fimbriae (fim D+)). The effect on E. coli isogenic strains 
were studied for both medium (Figure 24) and low viscosity silicone oil at the same time. Thus, the 
untreated controls were the same. T1F = Type 1 fimbriae. L = Low viscosity.   
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4.3.4 Curli fimbriae is a major target for biofilm formation by Gram-negative 
bacteria 
We used the isogenic mutants of E. coli #12 lacking curli, cellulose or type 1 fimbriae (fim 
D), alone or in combination, to evaluate to what degree different bacterial virulence factors 
influenced biofilm formation on polypropylene plastic. The combination of all three 
virulence factors promoted most new biofilm formation, whereas absence of type 1 
fimbriae significantly decreased biofilm formation. E. coli expressing type 1 fimbriae with 
or without cellulose only added to a low degree to biofilm formation (Figure 24 and Figure 
25). Silicone oil did not influence the growth rate of E. coli #12, S. aureus nor C. albicans 
(Figure 26). Thus, we postulated that silicone oil has a direct impact on at least one of these 




Figure 26. Number of colony forming units (CFU) analyzed using viable count. Increase in CFU is depicted 
with and without silicone oil in polypropylene tubes demonstrated with a log scale/mL for (A) E. coli #12, (B) 
S. aureus and (C) C. albicans. Control, bacteria only, cultured in polypropylene tubes: Black line; Bacteria 
grown with medium viscosity silicone oil in polypropylene tubes: Dotted line. 
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When exposing the curli-expressing E. coli strains to medium viscosity silicone oil, we 
found a significant decrease in biofilm growth (Figure 24 and Figure 25; p<0.0001), but 
this was not seen in isogenic curli deficient strains. Likewise, medium viscosity silicone oil 
did not alter biofilm production by type 1 fimbriae or cellulose. Overall, our results showed 







Figure 27. Medium viscosity silicone oil did not have a significant impact on the attachment of E. coli #12, S. 
aureus or C. albicans to polypropylene or on fungal hyphae. Nevertheless, P. aeruginosa adhered less to 
polypropylene (p<0.05). Number of colonies in mature biofilm after 72 hours of growth determined by 
viable count are depicted in log scale CFU/mL. (A) E. coli #12 (B) P. aeruginosa (C) S. aureus (D) C. albicans. C. 
albicans staining was achieved from overnight growth in yeast-peptone-dextrose (YPD) broth in 30°C. (E; 
upper panel) C. albicans cultured in polypropylene tubes, (E; lower panel) C. albicans cultured in medium 
viscosity coated polypropylene tubes. We used Blankophor p to stain C. albicans (E; right panel). Septum are 
highlighted with white arrows. We did not notice differences in the fungal hyphae. P-value: * ≤0.05. 
C. albicans
A E. coli #12 B P. aeruginosa C S. aureus






































































4.3.5 Mature biofilm induces less P. aeruginosa adhesion  
We did not find any significant difference of viable count (CFU/mL) for E. coli #12, S. 
aureus and C. albicans in mature biofilm (Figure 27A, C-D). Nevertheless, P. aeruginosa, 
adhered to a lower extent to polypropylene (p<0.05) (Figure 27B).  
4.3.6 Morphology of C. albicans hyphae after exposure to silicone oil 
We did not observe any change in C. albicans hyphae after overnight exposure to medium 
viscosity silicone oil. Budding cells and septum were clearly seen with and without silicone 
oil (Figure 27E). 
4.4 STUDY IV  
4.4.1 Effect on capacitance measurement by albumin  
We analyzed 477 measurements without and 472 measurements with silicone oil, 
respectively. During the 24th hour, 29 measurements were excluded as readings were too 
few to extract a reliable average. Moreover, in a few cases the liquid container was emptied 
and the pump ran dry before the end of the 24th hour measurement period. The maximum 
capacitance value was 790 in the group without and 633 in the group with silicone oil, 
respectively. The mean increase in capacitance was 257±96 in the group without and 
105±32 in the group with silicone oil, respectively. After ten hours of registration 
differences between the groups reached statistical significance (p=0.011, Table 10). The 
buildup of albumin coating over time is summarized in Figure 28, shown as the mean of 
the minimum capacitance, with and without silicone oil. The additional experiments with 
0.3 g/L and 1.0 g/L albumin solution with 379 and 190 measurements, respectively, did not 
show significant differences in capacitance with and without silicone oil during the 23-hour 



















 Table 10. Capacitance parameters and change over 23 hours with albumin solution (3 g/L).                                        








































1 381 433 405 406 12 382 415 406 401 10 0.176 
2 413 458 433 433 11 406 464 438 434 17 0.56 
3 417 471 439 439 15 407 482 437 441 18 0.839 
4 417 479 447 444 17 418 488 443 449 19 0.756 
5 406 510 454 451 21 426 506 446 456 26 0.914 
6 422 497 452 453 19 416 554 450 459 36 0.903 
7 426 506 457 457 19 420 566 457 468 39 0.675 
8 426 508 455 458 19 418 583 460 477 45 0.386 
9 423 499 454 457 17 423 590 479 488 48 0.062 
10 425 500 458 458 18 419 614 485 496 51 0.011 
11 419 507 460 461 19 436 614 503 511 52 <0.001 
12 425 508 461 462 19 437 627 522 523 57 <0.001 
13 428 505 473 468 20 454 649 524 534 58 <0.001 
14 436 487 469 467 15 467 670 524 541 66 <0.001 
15 441 500 480 476 17 456 716 560 561 71 <0.001 
16 430 503 478 476 19 447 727 545 567 76 <0.001 
17 440 513 485 481 19 454 760 572 585 81 <0.001 
18 441 520 488 483 22 452 754 596 600 79 <0.001 
19 440 544 490 493 24 452 759 645 615 81 <0.001 
20 437 535 497 496 24 479 729 659 639 65 <0.001 
21 439 554 502 504 32 470 788 659 652 71 <0.001 
22 440 556 502 501 27 494 790 670 665 63 <0.001 










Figure 28. A. Mean capacitance measurements caused by an albumin solution during 23 hours coating 
for devices without (green) and with (blue) addition of silicone oil. B. Median, maximum and minimum 
capacitance values caused by an albumin solution for each hour with and without addition of silicone oil. 
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4.4.2 Effect on capacitance measurements by free hemoglobin  
In total 484 measurements without and 414 with silicone oil were compared. The mean 
concentration of fHb in the prepared mixtures was 0.0141 g/L, ranging from 0.0056 g/L to 
0.0173 g/L. The mean concentration in the group with silicone oil was 0.0113 g/L and 
0.0125 g/L in the group without. The mean increase in capacitance was 190±174 with 
silicone oil and 324±78 without. A significant difference between the groups was seen after 
20 hours and onwards (Table 11). The last two hours of measurements were excluded from 
the analysis as the readings during the 23th and 24th hours did not result in sufficient number 
of readings to test for differences. Figure 29 depicts the mean increase in capacitance due 
to buildup of fHb coating over time in the group with and without silicone oil, respectively.  
 
 
Table 11. Capacitance parameters and change over 22 hours with free hemoglobin solution (0.01 g/L). 
 























1 379 414 396 396 11 378 411 393 393 10 0.09 
2 406 641 449 449 49 404 496 451 451 26 0.266 
3 398 650 462 462 51 416 563 470 470 33 0.272 
4 427 530 467 467 22 417 534 472 472 31 0.542 
5 432 539 479 479 24 417 561 476 476 35 0.649 
6 432 561 490 490 27 408 691 490 490 58 0.642 
7 433 575 499 499 30 414 773 511 511 89 0.652 
8 434 591 505 505 31 414 798 507 507 87 0.327 
9 435 601 505 505 32 411 843 540 540 125 0.724 
10 430 752 522 522 66 415 881 579 579 158 0.622 
11 429 779 523 523 74 404 880 596 596 175 0.922 
12 431 765 522 522 73 404 874 612 612 177 0.518 
13 433 767 520 520 74 410 873 638 638 177 0.257 
14 431 761 516 516 73 403 862 646 646 179 0.232 
15 438 783 518 518 79 399 866 666 666 178 0.164 
16 451 777 521 521 79 422 873 676 676 179 0.176 
17 456 767 516 516 81 421 877 686 686 183 0.091 
18 454 776 516 516 83 402 880 700 700 179 0.058 
19 448 784 522 522 83 406 873 703 703 181 0.06 
20 433 775 528 528 93 420 878 707 707 183 0.031 
21 428 818 557 557 113 409 897 711 711 186 0.037 
22 428 824 564 564 117 412 907 716 716 189 0.028 








Figure 29. A. Mean capacitance measurements caused by a free hemoglobin solution during 22 hours 
coating for devices without (blue) and with (green) addition of silicone oil. B. Median, maximum and 
minimum capacitance values caused by a free hemoglobin solution for each hour with and without addition 




5.1 VALIDATION OF A CAPACITANCE-BASED AUTOMATIC URINOMETER 
The best way to evaluate a new measuring device is to compare it with preferably the gold 
standard methods. Thus, in Study I and II we measured hourly measurement UO with the 
gold standard, a laboratory cylinder, and compared it with data acquired with the MU or the 
AU. The chosen study design permitted the comparison between the MU and the AU. The 
scientific scale is an alternative to the measuring cylinder and has two advantages as it is 
automatic and avoids visual assessment of UO. However, we chose not to use a scale as, 
based on our earlier studies (98), it is very sensitive to movements, which will easily distort 
measurements. 
5.1.1 Evaluation of a new automatic urinometer in adults (Study I) 
In brief, the new AU, using a capacitance measuring technique, was non-inferior to the 
MU, and scored significantly better regarding bias, temporal deviation and nursing staff 
judgement.  
In Study I, the bias of the AU was significantly lower when compared with the MU. This 
corresponds to a 24-hour bias of 46 mL with the AU compared with 126 mL with the MU. 
Both these values may be good enough in clinical use, while a smaller bias is desirable. 
Single errors of this size would not change clinical therapy in our view. The level of 
precision did not disagree significantly between the AU and the MU. Both urinometers 
were in our view equivalently effective in detecting oliguria, although the number of 
patients were too few to give a conclusive answer in this respect. 
As depicted in Figure 17, the bigger range of the dots at larger volumes in both plots 
indicates a worse precision at larger volumes. With the AU this may possibly be caused by 
a minor mismeasurement reoccurring for each siphon measurement, while with the MU this 
may be due to the inexact grading of the MU at large volumes and to an incorrect angle 
between the evaluator’s eyes and the horizontal surface level of the urine in the MU. When 
a Bland-Altman plot deviates at larger means, the ratio of the difference and the mean can 
be drawn on the y-axis in place of the difference (99). We believed this method unsuitable, 
as this alternative would have transferred the error from high absolute divergences among 
large means to large relative divergences midst small means. Furthermore, we prefer 
absolute values clinically. The propensity towards skewness in the histogram of the MU 
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may imply that visual reading of the analogue scale of the MU largely overestimates the 
UO (Figure 18).  
The possible question is what happens when the level of urine increases in the container 
(which would happen within 72 hours). However, only 16-18 mL of urine is collected in the 
measuring chamber of the AU before it is emptied automatically by a siphon mechanism 
into the collection bag. Although urine is emptied into the collection bag, oil will remain 
stuck onto the walls of the measuring chamber. Otherwise, the addition of the oil capsule 
would not have prevented the signal loss of the capacitance measurement that was 
registered and clinically observed before its introduction. 
Hersch et al. used a similar study design when assessing an AU using a droplet counting 
technique (100). They also found their AU superior to the MU regarding bias, precision and 
user friendliness. When comparing their AU, based on droplet counting, with our tested AU 
which uses capacitance measurements, one should consider the following: The bias with the 
capacitance technique was +1.9 mL (SD ±7.7 mL), which is comparable with +0.08 mL 
(SD ± 14 mL) with the droplet counting technique. However, the bias of the MU in our 
study was +5.3 mL (SD ±8.4 mL) compared with the much higher value +13 mL (SD ±68 
mL) in the study by Hersch et al. While the brand of the MU was identical in both studies, 
we do not know if the same models were applied, because Hersch et al. did not specify 
which model they utilized.  
Goldman et al. compared an AU based on a temperature exchange electronic sensor 
technique (Clarity RMSÔ, RenalSense, Israel) with an MU using a scientific scale instead 
of a measuring cylinder as a gold standard. They found a mean UO difference for the AU-
scale of −2.55 mL (95% CI, −4.3 to −0.8), and a mean difference for the MU-scale of +8.5 
mL (95% CI, 5.4 to 11.7). Whereas the Clarity RMSÔ slightly underestimated the 
measured volume, the capacitance-based AU Sippi® that we tested slightly overestimated 
the volume, but to a nearly identical degree (−2.55 mL vs. +1.9 mL). The bias of the MU 
was somewhat smaller in our study compared with their study (+5.3 mL vs. +8.5 mL). 
Notably, the measurement precision was considerably and significantly lower with the 
Clarity RMSÔ (SD 25.8 mL) compared with the Sippi® that we tested (SD +7.7 mL).  
5.1.1.1 Temporal deviation of measurements with a manual urinometer  
One error which may occur when assessing UO is temporal deviation of measurements that 
additionally may lower the precision of the MU. Conversely, this error is intrinsically 
circumvented with the AU using its built-in precision clock. In Study I, the mean time-
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based variation of the MU was ±7.4 minutes, compared with no temporal variation with the 
AU (p<0.0001). This is equivalent to a mean time error of ±12.4% and similar to the 16% 
found by Kramer et al. in manual monitoring UO in a standard ICU (24). In our view, this 
type of error may have clinical consequences. 
5.1.2 Evaluation of a new automatic urinometer in children (Study II) 
In Study II we investigated the capacitance-based AU in children, whereby we specifically 
adapted the AU by using a double-lumen tube instead of the normal single-lumen tube 
between the patient´s urinary catheter and the AU measuring device without changing the 
type or length of the tube. We did this for two reasons. Firstly, we kept both setups as 
similar as possible excluding for the measuring component, to improve the transit of small 
urine volumes. When a long single-lumen tube is used, small volumes of urine may get 
trapped without getting to the measuring chamber because of a negative pressure. Secondly, 
with a double-lumen tube, large urine volumes may flood the measuring chamber too 
quickly, when pressure differences between the two tubes are even out, resulting in 
miscalculation.  
In Study II, the bias of the AU when extrapolated for 24 hours was 26.4 mL versus 14.4 
mL for the MU group. Such daily biases are in our view acceptable in clinical practice and 
should likely not change clinical decisions. Largely, the AU underestimated UO somewhat, 
opposing the results in Study I. Conceivably, the double-lumen tube induced a too fast 
urine flow for the AU sensors when very high volumes occurred, depicted by a negative 
bias in the weightiest children with large urine volumes.  
To our knowledge, this is the first and only published study evaluating an AU among 
pediatric patients. 
5.1.3 Nursing staff´s evaluation of a manual versus an automatic urinometer 
A prerequisite to get a new device accepted in clinical routine is that the staff get the 
necessary theoretical and practical training education. Thus, the staff’s judgment of the new 
device after the training is of paramount significance. Both Study I and II began with a 15 
minutes theoretical summary of the device including its handling, where after the nursing 
staff used the device during 3 days. Finally, the nursing staff filled out the questionnaire 
about the devices.  
In Study I, the AU, while indeed at large preferred by the staff, did not score 
extraordinarily much better than the MU (Table 6). This is plausible because the AU device 
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at the time of the study did not automatically transfer UO data to the patient data 
management system. One may expect that the use of automatic data transfer would have 
increased the ratings of questions 2, 3 and 5, indicating an additional increase in staff 
satisfaction with the AU.  
Compared with the cardiothoracic ICU nursing staff’s evaluation in Study I (Table 6), the 
pediatric ICU nursing staff (Study II) (Table 9) generally rated the AU slightly higher, 
except for question 4 about reliability of UO measurement. Here, 85% of the cardiothoracic 
ICU nursing staff graded the AU higher, compared with 72% for the pediatric ICU nursing 
staff. Interestingly though, 28% of the pediatric ICU nursing staff thought the reliability 
was the same between the AU and the MU, compared with 7% of the cardiothoracic 
nursing staff. Also, for question 5, 68% of the adult cardiothoracic ICU nursing staff 
compared with 28% of the pediatric ICU nursing staff considered that neither of the devices 
gave them more time for other activities. Interestingly, 72% of the pediatric ICU nursing 
staff considered that the AU rendered more or much more time for other activities. These 
differences between our two studies may have many explanations. The introduction and 
teaching of the new AU may have differed between the ICUs. It is of uttermost importance 
that all the staff is familiar with all the features of the AU before starting the study, 
otherwise this might take extra time and energy. The fact that the system at the time of the 
studies was not linked to PDMS and thus obliged the nurse to manually record the UO may 
also have played a role. The more positive view of the pediatric nursing staff regarding the 
use of the AU may also be due to the fact that the UO are lower in children and that the 
measuring procedure, including making sure that the urinary catheter and the tube between 
the catheter and the UO measuring device is not kinked, is easier. Although a majority of 
the nurses in both the adult and the pediatric ICU regarded that they had a lot less or less 
contact with the urine bag of the AU compared with the MU, a fair part of the participating 
nurses in both ICUs felt they had the same degree of contact with both the AU and the MU. 
Normally, regular physical contact should not be needed with the AU. However, in this 
case, it may be explained by the novelty of the product and the need of reassuring its 
functionality. The argument that the AU saves time for the staff was demonstrated in the 
evaluation for both the adult and pediatric ICU patient. The nursing staff’s positive opinion 
of the AU in Study I and II are in line with the study by Hersch et al (23), where the 
nursing staff evaluated a droplet-based AU called Urinfo 2000, which, however, is no 
longer commercially available. 
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5.2 REDUCTION OF BIOFILM FORMATION 
Biofilm is a vital part of many infections. It weakens the penetration of antimicrobials and 
obstructs the response of the intrinsic immune system (39, 101). There is a need to decrease 
biofilm formation as it may promote infection of medical equipment, including temporary 
urinary and central venous catheters, permanent pacemakers and prosthetic heart valves 
(102). Thus, new efficacious methods to prevent biofilm formation are sought for. In Study 
III, we found that the type of used plastic material affected the growth of biofilm. The least 
quantity of biofilm was produced when bacteria were cultured on silicone oil covered 
polypropylene plastic. Additionally, curli fimbriae of E. coli were recognized as the 
principal target of silicone oil. 
5.2.1 Impact of plastic and silicone oil on microbial biofilm formation 
In Study III we studied polypropylene plastic as this is the plastic used in the measuring 
chamber of the studied AU. Polypropylene plastic alone reduced biofilm formation by E. 
coli #12 and C. albicans more than polystyrene, an alternative plastic applied in many 
medical equipment and devices. This polypropylene effect is deemed to its relatively 
slippery surface (81, 82). Due to the non-polar and hydrophobic properties attributed to 
polypropylene, silicone oil will accumulate as droplets on the surface of polypropylene. 
Based on the chemical structure and an initial pilot study using Raman microscopy 
(unpublished data), some amount of the hydrophobic oil will attach to the polypropylene 
plastic surface, in the form of droplets, and in doing so exerts the long lasting clinically 
observed effect despite surfaces being intermittently exposed to air between each emptying 
of the measuring chamber. Clinical observations and Study IV, suggest that supplementing 
silicone oil to polypropylene plastic impedes biofilm formation, prolonging adequate 
function of the AU.  
One also has to consider the biofilm formation at the liquid/air interface, where biofilms 
like pellicles are formed. This can be selectively advantageous for aerobic or facultative 
aerobic bacteria. Wang et al. have previously demonstrated that loss of O-antigen was 
associated with enhanced pellicle formation (103). In Study III we observed that biofilm 
was formed on the liquid/air interface. Moreover, we observed biofilm components like 
pellicles on the surface of the liquid. We carefully stained the biofilm at the liquid/air 
interface. 
In Study III, we found that the low as well as the medium viscosity silicone oils equally 
prohibited biofilm formation by common bacteria, implying that the grade of the silicone 
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oil viscosity did not have a significant impact on biofilm formation. In our view, silicone 
oil has a direct effect on biofilm formation, as silicone oil did not affect the bacterial 
growth. Our data indicate that silicone oil affects the biofilm promoting structure curli, 
without or with only minor impact on type 1 fimbriae or cellulose. Moreover, our viable 
count data corroborates that the decrease of biofilm is due to inhibition of extracellular 
matrix production and in the case of E. coli, this seems to be mediated via curli fimbriae.  
Fungi, including C. albicans, can similarly to bacteria form biofilm and initiate lower 
urinary tract infections (38). Our finding in Study III that both polypropylene and silicone 
oil significantly decreased biofilm formation expressed by C. albicans is of clinical 
importance. In fact, Odabasi and Mert reported that 22% of patients remaining more than 
one week in an ICU had candiduria that in turn could significantly be linked to increased 
mortality (104).  
The new AU contains a silicone oil capsule, which is liquefied by urine, where after 
silicone oil covers the surface of the polypropylene plastic measuring chamber. In Study 
III we demonstrated that the polypropylene plastic silicone oil interaction significantly 
decreased biofilm formed by common bacteria and candida, whereby the function of the 
device was prolonged and possibly may reduce the risk of an ascending urinary infection.  
In Study III, we chose to focus on the polypropylene plastic used in the actual device. The 
choice of polypropylene plastic originally was made after clinical observations that 
polypropylene in combination with silicone oil proved benefits in terms of functional 
duration of the device. We decided to include polystyrene primarily to investigate whether 
the plastic on its own, without oil, could impact the amount of biofilm formation. However, 
including a plastic that could serve as a “better” positive control would most probably have 
been relevant, both in order to study the underlying mechanisms and to identify the main 
target. 
Silicone oil could potentially target other components of the bacteria and the bacterial 
biofilm, which we did not test in Study III. Instead, we focused on E. coli, being an 
important pathogen and the major biofilm components curli, cellulose and type 1 fimbriae. 
To elucidate the bacterial biofilm targets we created knock out strains, allowing us to 
investigate the impact of these components. In Study III, we were able to clearly 
demonstrate the impact of curli. However, Klebsiella spp have not been shown to be 
equipped with curli or cellulose (105) and other components are therefore relevant for the 




5.2.2 Impact of silicone oil on biofilm caused by albumin and free 
hemoglobin  
The main finding of Study IV was that silicone oil significantly decreased the capacitance 
increase produced by coating of albumin or fHb solutions on the surface of the measuring 
chamber of the studied capacitance-based AU, which already had been validated to 
continuously measure UO in Study I and II (30, 106, 107). However, before performing 
Study I and II we had clinically experienced that biofilm coating of the AU by fHb and 
albumin in urine from patients undergoing cardiac surgery with CPB affected AU 
measurements. This initiated the manufacturer to include a water-dissolvable capsule 
containing silicone oil in its antechamber before we conducted Study I and II. However, 
we still wanted to investigate the impact of fHb and albumin on the new version of the AU 
with an enclosed silicone oil (Study IV). 
In Study IV, both the albumin (3 g/L) and the fHb solution significantly amplified the 
capacitance measurement in the AU. Silicone oil released from the antechamber of the AU 
significantly decreased those increases in capacitance during the 23-hour study period, by at 
least partially prevent biofilm formation in the measuring chamber. To our knowledge, this 
is the first investigation indicating at least partial protection of an albumin and fHb biofilm, 
respectively, on plastic surfaces by use of silicone oil. 
In a large clinical study involving 1200 patients undergoing coronary surgery (52), 80% of 
patients had early postoperative albumin levels in urine of 0.05 g/L or lower. Thus, our 
studied albumin solution 3 g/L had a significantly higher concentration than the 
concentration of albumin in urine found postoperatively in at least 80% of patients 
undergoing conventional cardiac surgery, implying that the beneficial effect of silicone oil 
should apply to the vast majority of conventional postoperative cardiac patients. 
5.3 CLINICAL IMPLICATIONS 
5.3.1 Study I and II 
When using an MU for measuring UO, the staff is required to read and empty the MU 
manually at specific time intervals. This is unfortunately frequently impractical or 
impossible due to shortage of nursing staff. However, if this is possible, Study I and Study 
II show that the MU measures hourly UO adequately and similarly to the AU. Yet, 
irrespective of staff number, the AU may give the staff the opportunity to perform other 
responsibilities. Likewise, using the AU in normal wards may allow hourly UO 
measurements in all patients with a urinary catheter, and not restrict measurements to 
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infrequent daily episodes. This may, together with laboratory kidney parameters, enable a 
faster and more accurate diagnosis using current AKI criteria. Theoretically, the higher 
measurement resolution that may be obtained with the AU should benefit early detection of 
an upcoming AKI. The AU may also potentially decrease the risk of retrograde urinary tract 
contamination, as it will minimize the nursing staff´s direct contact with the system and 
avoid the requirement for the nursing staff to bend down with possible contamination of 
clothes or hands from the floor or bed while reading the scale of the MU. Another 
disadvantage of the MU may ensue during high UO. If the UO tops 500 mL/hour, the MU 
will not include the complete volume in the measuring chambers, and the volume above 
500 mL with be drained directly into the urine bag. Thus, this surplus volume can only 
roughly be judged hourly if the urine bag is emptied or measured with the inexact scale of 
the urine bag. However, in Study I we circumvented this potential problem by emptying 
the urinary bag hourly.   
We are not aware of the costs of the AU but according to the manufacturer the price setting 
will probably be close to that of the MU. When the exact cost is known, one could conduct 
a cost-effectiveness study. The clinician has to evaluate the potential added value of the 
AU, when taking into consideration its potential advantages including time saving in low 
staffed wards and possibility of automatic data transfer avoiding human errors in data 
entries. 
In addition to the silicone oil of medium viscosity applied in the measuring chamber of the 
AU, a supplementary low viscosity silicone oil that coats the proximal end of the tubing 
towards the AU could potentially have additional advantages. Moreover, reiterating silicone 
oil would recoat the surface. 
5.3.2 Study III  
The findings in Study III may support the development of novel surfaces that repel biofilm 
formation. Upcoming studies need to investigate the duration of silicone oil on biofilm 
formation and the potential clinical benefit in this respect of the new AU. Silicone oil, in 
contrast to silicone, has so far not been used in the urinary catheters, but we believe this 
may be beneficial. However, this has to be evaluated in a follow-up trial and the effect will 
probably depend on the plastic used in the urinary catheter, the amount of delivered silicone 
oil and the frequency of oil replenishment. 
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5.3.3 Study IV 
The clinical importance of Study IV is that supplementation of silicone oil in the 
capacitance-based AU allows for prolonged measurements of trustworthy UO until its 
throwaway part has to be substituted. This would be of value in patients with fHb and/or 
albumin in urine, which often is the case for example in patients who have undergone 
cardiac surgery with CPB, in patients with diabetes mellitus, and in patients with renal 
dysfunction. Indeed, we have not seen failed AU measurements early after cardiac surgery 
since silicone oil was included in AU. 
5.4 LIMITATIONS 
5.4.1 Study I 
First, we did not randomize the patients. Instead, we allocated patients to the urinometer 
that was currently in use. Thus, we performed Study I during two stages, whereby we first 
investigated the MU, followed by an evaluation of the AU. Second, there was a difference 
in the mean of the hourly urine cylinder reference measurements between the MU and the 
AU groups whereby a higher mean was found in the MU group. This may have been a 
potential bias. However, we found similar results in both ranges compared to the overall 
result when we performed subgroup analyses that demarcated each urinometer group at 
hourly UO values of 100 mL (Table 4). Furthermore, we omitted measurements if the 
nursing staff had unintentionally placed the AU or the MU erroneously. This occurred 
almost solely when the nursing staff mobilized the patient from the bed to a chair. 
Additional education should help to prevent this problem with both the AU and the MU, 
although this drawback is likely not distinguished as clearly with the MU as with the AU. 
Third, one could argue that only 408 comparisons were made in 36 post cardiac surgery 
patients (less than 12 hours per patient). This seems to be short compared with the ICU 
length of stay for cardiac surgery patients. However, a similar study with a droplet-based 
AU (23) included 453 measurements and was the base for our power calculation. Our 
measurements were for practical reasons not conducted during nighttime, as a laboratory 
technician was needed to conduct the reference measurements. 
5.4.2 Study II 
First, as in Study I, we did not randomize patients in Study II and instead allocated the 
patients to either the MU or the AU. Second, one might see the variation of number of 
measurements per patient as a selection bias. Third, there were fewer measurements with 
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the MU than with the AU (83 vs. 127), and the number of patients in each group, though 
similar, were few, with six patients in the MU group and eight patients in the AU group. 
Study II should rather have included more patients and several centers. Fourth, more 
diverse patients and specifically patients with manifest oliguria would have been preferable. 
However, assuming a cutoff for oliguria at <0.5mL/kg/h, 9% and 7% of the measurement in 
the AU and MU group, respectively, were oliguric. Anyway, we consider performing a 
larger study taking these points into consideration. Fifth, one may ask why there were wide 
fluctuations with both the AU and the MU, specifically in the nine cases with biases above 
10 mL. In fact, there were five instances with biases of more than 10 mL, three with the AU 
and two with the MU in four patients. Regarding the AU, the measurements surrounding 
the measurements with high bias (measurements one hour before and one hour after) were 
normal (<5mL bias). We can only speculate about the reasons. Of course, there may have 
been inaccurate measurements involved with any of the measuring methods including the 
cylinder. 
Lastly, as the AU adapts the measurement of urine to the position of the device and sets off 
an alarm should the position interfere with measurement, it is conceivable this is a potential 
issue given the often very frequent movement of the pediatric ICU patient. However, before 
the start of Study II, we had a rather large experience of using the AU in the adult ICU, and 
the alarm set off for position interference with measurement very infrequently, in fact only 
when the patients were transported for external evaluations, like CT-scans. Neither in 
pediatric nor in adult patients did we experience alarms due to movements by the patient 
while still in the bed. 
5.4.3 Study III 
First, we did not measure the exact width of the silicone oil coating and how the silicone oil 
was dispersed in the wells. One could presume that there should be more oil in the bottom 
of the well than on the walls, as oil is likely to slide down. Indeed, we detected more 
biofilm on the walls compared with the bottom of the wells. Conversely, this may as well 
be explained by how biofilm is formed (108). Anyway, we assumed that the quantity of oil 
on the walls was similar between wells. Still, further studies should quantify the spreading 
of silicone oil in the measuring chamber of the AU as well as if oil thickness varies over 
time. Second, we do not know for how long the influence of silicone oil lasts. In Study III, 
we recorded measurements for 72 hours, because most patients using the AU will not stay 
longer in the ICU after cardiac procedures. Furthermore, we found that the biofilm 
formation reached a plateau phase after 72 hours.  
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5.4.4 Study IV 
First, in Study IV we applied Ringer’s acetate as a surrogate for normal urine. Admittedly, 
we may have utilized more complex formulas for artificial urine (109), but we chose to use 
Ringer’s acetate as it is cheap and clinically accessible and mixes well with albumin and 
fHb. Moreover, it is both difficult and expensive to make large quantities of sterile artificial 
urine. There were several arguments against using humane urine. We would have needed 
approximately 80 L of human urine, which also may have a large interpersonal variation in 
electrolyte composition and pH, and it is complicated to keep such large volumes sterile. 
Indeed, other investigators have applied similar solutions as we did to replace human urine, 
e.g. Rasmussen et al. studied ascending infections using 0.9% saline (110). Second, our 
experiments were restricted to 24 hours, and with a longer follow-up time we might have 
seen significant effects with both the 0.3 and 1.0 g/L albumin solution. Third, the 
concentration of fHb varied somewhat between each run. However, the mean difference in 
concentration in fHb was very similar between both groups and should accordingly only 
marginally have had an impact on the results (0.0113 g/L with silicone oil and 0.0125 g/L 
without silicone oil). Interestingly, fHb concentrations in urine in patients with discolored 
urine in the first hours after cardiac surgery with CPB, typically fluctuate between 0.1 to 5 
g/L in our cardiothoracic ICU, after which it regularly drops. Thus, in our study we used a 
fHb concentration that was approximately 10% of the real values at most. Conversely, we 
have not experienced malfunctioning measurements in our clinical routine since we started 
to use the new AU Sippi® device with an enclosed water-soluble capsule with silicone oil. 
Fourth, Study IV was neither randomized nor blinded, but as data measurements were 




































































The specific conclusions were: 
 
• This study compared the performance of a new capacitance-based AU with that of an 
MU in adult patients in a cardiothoracic ICU. The AU was non-inferior to the MU 
regarding precision, and significantly better than the MU in terms of bias, temporal 
deviation and staff opinion.  
 
• When the modified capacitance-based AU was compared with a standard MU in a 
pedatric intensive care unit for children weighing ≤10 kg, the urinometers were 
comparable regarding bias of measurements. Staff consistently rated the modified AU 
significantly higher than the MU in terms of user friendliness, time-consumption and 
duration of contact with the urine bag.  
 
• A silicone oil-coated polypropylene plastic surface, as used in an AU, significantly 
decreased early biofilm formation by pathogenic bacteria, including ESBL-producing 
and multidrug resistant strains, as well as C. albicans. Both low and medium viscosity 
silicone oils significantly reduced early biofilm formation to a similar extent. 
 
• Curli fimbriae appeared to be the tentative silicone oil target and addition of silicone 
oil led to a 50% reduction in biofilm formation in curli-positive strains. No additional 
reduction in biofilm formation could be detected when adding silicone oil to curli 
deficient strains.  
 
• Albumin or free hemoglobin coating of the capacitance measurement membrane of 
the AU decreased the capacitance measurement capability of the AU, and this could 
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